Selective Recognition of H3.1K36 Dimethylation/H4K16 Acetylation Facilitates the Regulation of All-*trans*-retinoic Acid (ATRA)-responsive Genes by Putative Chromatin Reader ZMYND8^{*}

Received for publication, July 21, 2015, and in revised form, December 10, 2015 Published, JBC Papers in Press, December 11, 2015, DOI 10.1074/jbc.M115.679985

Santanu Adhikary^{‡§1}, Sulagna Sanyal^{‡1}, Moitri Basu^{‡2}, Isha Sengupta[‡], Sabyasachi Sen[‡], Dushyant Kumar Srivastava^{§2}, Siddhartha Roy^{§3}, and Chandrima Das^{‡4}

From the [‡]Biophysics and Structural Genomics Division, Saha Institute of Nuclear Physics, 1/AF Bidhannagar, Kolkata-700064 and the [§]Structural Biology and Bioinformatics Division, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology, 4 Raja S.C. Mullick Road, Kolkata-700032, India

ZMYND8 (zinc finger MYND (Myeloid, Nervy and DEAF-1)type containing 8), a newly identified component of the transcriptional coregulator network, was found to interact with the Nucleosome Remodeling and Deacetylase (NuRD) complex. Previous reports have shown that ZMYND8 is instrumental in recruiting the NuRD complex to damaged chromatin for repressing transcription and promoting double strand break repair by homologous recombination. However, the mode of transcription regulation by ZMYND8 has remained elusive. Here, we report that through its specific key residues present in its conserved chromatin-binding modules, ZMYND8 interacts with the selective epigenetic marks H3.1K36Me2/H4K16Ac. Furthermore, ZMYND8 shows a clear preference for canonical histone H3.1 over variant H3.3. Interestingly, ZMYND8 was found to be recruited to several developmental genes, including the all-trans-retinoic acid (ATRA)responsive ones, through its modified histone-binding ability. Being itself inducible by ATRA, this zinc finger transcription factor is involved in modulating other ATRA-inducible genes. We found that ZMYND8 interacts with transcription initiation-competent RNA polymerase II phosphorylated at Ser-5 in a DNA templatedependent manner and can alter the global gene transcription. Overall, our study identifies that ZMYND8 has CHD4-independent functions in regulating gene expression through its modified histone-binding ability.

ZMYND8 (zinc finger MYND (<u>My</u>eloid, <u>N</u>ervy and <u>D</u>EAF-1)-type containing <u>8</u>) is a putative chromatin reader/effector harboring a PWWP domain, a bromodomain, and a PHD type

zinc finger. It associates with the CHD4 protein of NuRD chromatin remodeling complex implicated in gene transcription, cell cycle progression, and genome integrity (1, 2). Reader proteins specifically recognize histone post-translational modifications (PTMs)⁵ and translate such recognition(s) into meaningful biological outcomes by virtue of either their intrinsic activities or those of their interacting partners (3). These readers may interpret histone PTMs via "monovalent" or "multivalent" recognition (4). In monovalent recognition, a chromatin reader recognizes one histone PTM. In contrast, in multivalent recognition, readers recognize multiple histone modifications intra/inter-nucleosomally. An accessible surface is provided by these readers (such as a cavity or surface groove), which accommodates the modified histone residues, and determines the modification (e.g. acetylation versus methylation) or state specificity (such as mono- versus trimethylation of lysine) (3).

ZMYND8 is a well known component of the transcription coregulator complex and is associated with several demethylase machinery components, including KDM5A, KDM5C, or LSD1 (5, 6). Through its ability to interact with Xenopus RCoR2, ZMYND8 plays a significant role in embryonic neural differentiation (7). Apart from this, ZMYND8 is also involved in T-cell lymphoma and breast and cervical cancer (8-10). Another interesting feature is that ZMYND8 is significantly involved in transcription activation (5). ATRA, a vitamin A metabolite, is a well known inducer of transcription of several genes. It modulates RA receptor (retinoic acid receptor/retinoid X receptor) dimerization at the retinoic acid-response element (RARE) (11). We show for the first time that ZMYND8 is ATRAresponsive and a substantial number of genes regulated by ZMYND8 harbor the RARE sequence. Interestingly, we found that ZMYND8 is involved in regulating transcription initiation through its interaction with the RNA polymerase II complex in a DNA-mediated manner. Furthermore, ZMYND8 can regulate global gene expression in a CHD4-independent manner. In an attempt to understand its mode of recruitment to chromatin, we found that it has a selective interaction with H3.1K36Me2/



^{*} This work was supported in part by research grants from Biomolecular Assembly, Recognition and Dynamics Project, Grant 12-R&D-SIN-5.04-0103 from the Department of Atomic Energy, and a Ramalingaswami Fellowship, Department of Biotechnology, Government of India to C. D. The authors declare that they have no conflicts of interest with the contents of this article.

¹ Both authors contributed equally to this work.

² Recipients of fellowships from Department of Biotechnology and Indian Council of Scientific and Medical Research, Government of India.

³ Recipient of Indian Council of Scientific and Industrial Research Network Project (UNSEEN) and Ramanujan Fellowship from Department of Science and Technology. To whom correspondence may be addressed: Tel.: 91-33-2499-5733; Fax: 91-33-2473-5197; E-mail: roysiddhartha@iicb.res.in.

⁴ To whom correspondence may be addressed. Tel.: 91-33-2337-5345 (Ext. 3106); Fax: 91-33-23374637; E-mail: chandrima.das@saha.ac.in.

⁵ The abbreviations used are: PTM, post-translational modification; co-IP, coimmunoprecipitation; ATRA, all-*trans*-retinoic acid; RA, retinoic acid; RARE, retinoic acid-response element; FAM, 6-carboxyfluorescein; qRT, quantitative RT; PHD, plant homeodomain; pol II, polymerase II.

H4K16Ac marks through its chromatin-binding module. Thus, this study establishes a new role of ZMYND8 in the context of its epigenetic recognition thereby regulating ATRA-induced gene transcription.

Experimental Procedures

Cell Culture and ATRA Treatment—HeLa and HEK293 cells were maintained in Dulbecco's modified Eagle's medium (Gibco, Invitrogen), and SH-SY5Y cells were maintained in DMEM/F-12 (1:1) (Gibco, Invitrogen). Neuro2A cells were maintained in Eagle's minimum essential medium (Sigma). All cell lines were supplemented with 10% fetal bovine serum (Gibco, Invitrogen) and penicillin/streptomycin (10 μ l/ml medium, Gibco, Invitrogen) at 37 °C in 5% (v/v) CO₂. SH-SY5Y cells were treated with 10 μ M ATRA (Sigma) or DMSO (Sigma, solvent control) for 2 or 4 days. Every other day, media change was given to the SH-SY5Y cells with ATRA.

Overexpression and siRNA Transfection—HEK293 cells were transiently transfected with FLAG-H3.1/H3.3 (for co-IP experiments) and FLAG-ZMYND8 and WT-/FLAG-ZMYND8 Δ PBP (for co-IP and ChIP), and HeLa cells were transfected with FLAG-ZMYND8 WT/ Δ PBP (for coimmunofluorescence) using Lipofectamine2000 (Invitrogen) as per manufacturer's protocol.

HeLa and SH-SY5Y cells were transfected with ZMYND8 siRNA (Santa Cruz Biotechnology) or negative control siRNA (Invitrogen) using INTERFERin[®] transfection reagent (Polyplus) according to the manufacturer's protocol and incubated for 24 h. For SH-SY5Y cells, prior to siRNA transfection, cells were treated with 10 μ M ATRA or DMSO for 24 h.

Cloning and Site-directed Mutagenesis—Individual domains PHD, Bromo, PWWP and a combination of all three (designated as PBP) of ZMYND8 were cloned in pDEST15 bacterial expression vector. PBP domain was also cloned in pDEST17 bacterial expression vector. ZMYND8 wild type and Δ PBP were also cloned in pCMV-FLAG mammalian expression vector. All the cloning vectors were from Gateway[®] cloning system (Invitrogen), and standard protocols were followed. All the clones were confirmed by sequencing. The point mutation was generated using QuikChange site-directed mutagenesis kit from Stratagene as per standard protocols (12).

Protein Purification-Transformed cells were grown until optical density reached 0.8 and was induced at 1 mM isopropyl 1-thio- β -D-galactopyranoside (Sigma) at 20 °C for 16 h. The cells were lysed in Lysis Buffer: 20 mM Tris-HCl (pH 8), 150 mM NaCl, 0.05% Nonidet P-40, 1 mM DTT, 2 mM PMSF, 1× protease inhibitor mixture (EDTA-free). After sonication, the lysate was spun down twice at 13,000 rpm, 4 °C, 30 min. The supernatant was subjected to glutathione-Sepharose beads binding for 2 h at 4 °C. The beads were spun down and washed with Wash Buffer: 20 mM Tris-HCl (pH 8), 500 mM NaCl, 1 mM DTT. The bead bound proteins were eluted with Elution Buffer: 20 mм Tris-HCl (pH 8), 150 mм NaCl, 100 mм reduced glutathione, 2 mM DTT. The eluted proteins were concentrated in Amicon Ultra Filter tubes (Millipore) and purified further by gel filtration chromatography using a Superdex75 column (GE Healthcare).

ZMYND8, Regulates ATRA-responsive Genes

Chromatosome Isolation—Chromatosome was prepared from freshly harvested HeLa cells as described elsewhere (13). Briefly, nuclear pellet of HeLa cells was digested with micrococcal nuclease (Sigma 0.2 units/ μ l) and extracted with TE buffer for 1 h. Concentrated chromatin was separated by sucrose gradient (5–40%) ultracentrifugation using Sorvall WXUltra100 (Thermo Scientific) in an AH650 rotor for 16 h at 35,000 rpm. Chromatin fractions were analyzed in agarose gel; chromatosomal fractions were pooled and dialyzed in TE buffer for further analysis.

CelluSpots Peptide Array Analysis—MODified Histone Peptide Array (CelluSpots array) was procured from Active Motif (catalogue no. 13005). CelluSpots array analysis was done as per standard protocol (14, 15). Briefly, the array was blocked with the Blocking Buffer overnight at 4 °C, washed three times with Wash Buffer, and incubated with GST-fused protein at a concentration of 1 μ M. The array was probed with anti-GST antibody.

Peptide Pulldown Assay—Peptides purchased from AnaSpec were as follows: H4K5Ac (64844-1); H4K8Ac (64843-1); H4K12Ac (64849-1); H4K16Ac (64847-025); H4K20Ac (65212-1); H3.1K36Me1 (64602-1); H3.1K36Me2 (64442-1); H3.1K36 Me3 (64441-1); H3.1K9Ac (63680); H3.1K14Ac (63682), and H3.1K27Ac (64637-1). Peptides purchased from EpiCypher were as follows: H3.3(22–44) (12-0020); H3.3K36Me1 (12-0022); H3.3K36Me2 (12-0023), and H3.3K36Me3 (12-0024).

Peptide pulldown assays were done as per standard protocol (16). Briefly, biotinylated histone peptides were incubated with GST-tagged protein in IP Buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.05% Nonidet P-40, 1 mM DTT) at 4 °C, overnight. The reactions were subjected to Streptavidin beads (GE Health-care) binding for 2 h at 4 °C and washed with IP Buffer, and the complex was pulled down and analyzed by Western blotting.

Protein-Protein Interaction Studies—The core histone and chromatosome interactions with GST and GST fusion proteins were performed as per standard protocol (5, 14). Briefly, proteins were incubated in an equal molar ratio in binding buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.05% Nonidet P-40, 1 mM DTT), pulled down by pre-blocked glutathione-Sepharose beads, and washed in binding buffer, and the protein complex was analyzed by Western blotting.

Fluorescence Spectroscopy and Analysis of the Binding Data— The fluorescence measurements were performed in an LS 55 luminescence spectrometer (PerkinElmer Life Sciences) at 25 °C. In the case of H3K36Me3, H3K36Me2, H3K36Me1, and H3K36 unmodified peptides, tryptophan fluorescence measurements were carried out on samples containing 0.45 μ M ZMYND8 (His-PHD/Bromo/PWWP) and dissolved in 20 mM HEPES (pH 6.5), 200 mM NaCl, 300 mM ammonium sulfate, 1 mM β -mercaptoethanol, while progressively increasing the peptide concentration in each case until there was no further change in the emission intensity with an increase in the peptide concentration. Samples were excited at 295 nm, and emission was recorded at 320 nm with a scan speed of 200 nm/s, and averaged over three scans.

In case of FAM-conjugated H4K16-acetylated and H4K16unmodified peptides, fluorescence measurements were carried out using 0.6 μ M of the peptides dissolved in 20 mM Tris-HCl



(pH 6.5), 150 mM NaCl, 1 mM β -mercaptoethanol at 25 °C with increasing addition of ZMYND8 (His-PBP). Samples were excited at 494 nm, and emission was recorded at 520 nm with scan speed 200 nm/s and averaged over three scans.

Following peptides were custom-synthesized from GL Biochem (Shanghai, China) Ltd. for the fluorescence spectroscopic studies 5-FAM-H4K16Ac, 5-FAM-H4K16 unmodified, H3.1K36Me3(29-40), H3.1K36Me2(29-40), H3.1K36Me1 (29-40), H3.1K36 unmodified(29-40). Results from fluorometric titrations were analyzed with the following method (17). The apparent dissociation constant (K_d) was determined using non-linear curve fitting analysis (Equation 1) according to Reaction 1,

$$L + P \Leftrightarrow LP$$

Reaction 1

Here, L is the ligand ZMYND8 (His-PBP), and P is the histone peptide used.

All experimental points for binding isotherms were fitted by least squares analysis as shown in Equation 1.

$$C_0 (\Delta F/\Delta F_{\rm max})^2 - (C_0 + C_p + K_d) (\Delta F/\Delta F_{\rm max}) + C_p = 0 \quad ({\rm Eq.~1})$$

where ΔF is the change in fluorescence emission intensity at 340 nm (excitation of tryptophan residue(s) at 295 nm) for each point of the titration curve. $\Delta F_{\rm max}$ is the same parameter when the ligand (ZMYND8 His-PBP) is totally bound to histone. C_p is the concentration of histone, and C_0 is the initial concentration of the ligand. A double-reciprocal plot was used for determination of $\Delta F_{\rm max}$ using Equation 2,

$$1/\Delta F = 1/\Delta F_{\max} + K_d(\Delta F_{\max}(C_p - C_0))$$
(Eq. 2)

In the case of titration of ZMYND8 (His-PBP) with H4K16 unmodified and H4K16Ac histone peptides, the data analysis was done following the same theory as reported above, and the non-linear curve fitting was done following Equations 1 and 2. The only difference being that in this case, C_0 is the initial concentration of the FAM-conjugated histone H4K16 unmodified and C_n is the concentration of the ligand ZMYND8 His-PBP.

Molecular Modeling Studies—Bromo-PWWP module of ZMYND8 was generated by MODELLER (18) package using chain A of 4N4G as a reference structure.

Coimmunofluorescence and Confocal Microscopy—Coimmunofluorescence staining was performed as per standard protocol (19). Briefly, the cells were fixed with 4% paraformaldehyde, permeabilized with 1% Triton X-100, and blocked with 3% BSA. Cells were incubated with anti-FLAG antibody (Sigma) and either anti-H4K16Ac (Active Motif) or H3K36Me2 (Abcam) antibody for 1 h. Following washes with PBST, the cells were incubated with Alexa Fluor 488- and Alexa Fluor 594-conjugated secondary antibodies for 1 h at room temperature. The coverslips were washed with PBST and mounted after DAPI staining. OLYMPUS FLUOVIEW FV1000 confocal scanning microscope was used for imaging.

Co-IP—Cross-linked cells were subjected to co-IP as delineated elsewhere (20). In brief, after cross-linking the cells were lysed with 50 mM HEPES (pH 7.5), 150 mM NaCl, 1.5 mM $MgCl_2$, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% sodium deoxycholate, 5% glycerol, 1 mM DTT, 2 mM PMSF, 1 mM trichostatin A, 5 mM sodium butyrate, and complete protease inhibitor mixture and incubated on ice for 1 h followed by centrifugation at 13,000 rpm for 10 min at 4 °C. After pre-clearing the lysates, immunoprecipitation was done with the antibodies, followed by washes with the same buffer, and the complexes were analyzed by Western blotting.

Chromatin Fractionation—Chromatin fractionation was done as per standard protocol (21) with some modifications. Briefly, cells were resuspended in TB Buffer (20 mM HEPES (pH 7.3), 110 mM KOAc, 5 mM NaOAc, 2 mM Mg(OAc)₂, 1 mM EGTA, 2 mM DTT, 2 mM PMSF, 1× protease inhibitor cocktail) containing increasing concentrations of Nonidet P-40 (0.1–0.5%). The pellet fractions were separated from soluble fractions by centrifugation at 13,000 rpm for 10 min at 4 °C. The pellet was treated with DNase I in TB Buffer containing 0.1% Nonidet P-40, 10 mM MnCl₂ at 37 °C for 30 min.

Chromatin Immunoprecipitation (ChIP)-ChIP assays were performed as per standard protocol (22). Briefly, cross-linking was done with 1% formaldehyde and then the reaction was stopped by 0.125 M glycine, followed by cell lysis in Cell Lysis buffer (5 mM PIPES (pH 8.0), 85 mM KCl, 0.5% Nonidet P-40 (with fresh protease inhibitor)). The isolated nuclei were resuspended in nuclei lysis buffer (50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 1% SDS (with fresh protease inhibitor)). After sonication of the chromatin, pre-clearing was done. Subsequently, chromatin was immunoprecipitated with anti-ZMYND8 (Sigma Prestige Group), anti-H4K16Ac (Active Motif), anti-H3K36Me2 (Abcam), anti-H4 (Abcam), and anti-H3 (Abcam) antibodies overnight at 4 °C. Dynabeads were blocked with 0.3 mg/ml salmon sperm DNA and set for interaction. Beads were washed with RIPA buffer, high salt buffer, LiCl buffer, and TE buffer, consecutively. Following RNase A and proteinase K treatment, the beads were kept for de-cross-linking at 65 °C. Phenol/chloroform extraction followed by ethanol precipitation was performed. The DNA pellet was dissolved in H₂O and then qPCR analysis was done using gene-specific primers.

ChIP assay in SH-SY5Y cells was performed after treating with 10 μ M ATRA or DMSO for 4 days. The primers used in ChIP assays were designed inside the gene body or promoter elements using the UCSC Genome Browser. The detailed primer information is available on request.

Western Blot Analysis—Whole cell extracts were prepared with Laemmli Buffer (4% SDS, 20% glycerol, and 120 mM Tris-HCl (pH 6.8)) and sonicated followed by boiling at 100 °C. The samples were electrophoresed on 7.5, 11, or 15% SDS-PAGE and transferred on nitrocellulose membrane followed by blocking with nonfat skimmed milk and probed for specific antibodies. Primary antibodies used are listed in Table 1.

Reporter Construct and Luciferase Assay—The 527-bp upstream promoter region of mouse *Zmynd8* gene was amplified by PCR using mouse genomic DNA as template and then cloned into pGL3 basic vector (Promega) at KpnI/HindIII site. Similarly, the 873-bp upstream region of human *ZMYND8* gene was cloned into pGL3-basic vector at KpnI/SacI site. The primer sequences used to clone the promoter regions are mentioned in Table 2 where the restriction enzyme sites are under-

TABLE 1	
The list of antibodies used in Western blotting, co-IP, ChIP, and immunofluorescence	е

Antibody	Company	Catalog No.
Anti-GST-HRP	GE HealthCare	RPN1236
Anti-FLAG-HRP	Sigma	A8592
Anti-FLAG monoclonal	Sigma	F1804
Anti-ZMYND8	Sigma	HPA020949
Anti-Tau	Santa Cruz Biotechnology	sc20172
Anti-GAPDH	Abcam	ab9485
Anti-tubulin α	AbD-Serotec	MCA78G
Anti-H3	Abcam	ab10799
Anti-H4	Abcam	ab10158
Anti-H3K36Me1	Abcam	ab9048
Anti-H3K36Me2	Abcam	ab9049
Anti-H3K36Me3	Abcam	ab9050
Anti-H3K9Ac	Millipore	07-352
Anti-H4K16Ac	Active Motif	39167
Anti-RNA pol II (N-20)	Santa Cruz Biotechnology	sc899
Anti-RNA polymerase II phospho-Ser-5	Abcam	ab5131
Anti-RNA polymerase II phospho-Ser-2	Abcam	ab24758
Anti-ZMYND11	Sigma	AV34704
Anti-rabbit IgG-HRP	Sigma	A1949
Anti-rat IgG-HRP	Sigma	A5795
Anti-mouse IgG-HRP	Promega	W402B
Anti-rabbit Alexa Fluor 488	Invitrogen	A11034
Anti-rabbit Alexa Fluor 594	Invitrogen	A11037
Anti-mouse Alexa Fluor 488	Invitrogen	A11029
Anti-mouse Alexa Fluor 594	Invitrogen	A11032

lined. All constructs were sequenced to confirm their identity. The mutation within the RARE in both human and mouse promoters was done by using QuikChange II XL site-directed mutagenesis kit (Agilent).

For reporter assay, 5×10^4 cells were seeded on 12-well culture plates. After 24 h, the pGL3-ZMYND8 construct (0.4 μ g) was transiently transfected with Lipofectamine 2000 (Invitrogen). After 4 h of transfection, the medium was replaced with a fresh incomplete one supplemented with either RA or DMSO for the next 16 h. Each transfection was normalized with pRL-CMV vector (0.04 μ g). The following day, cells were harvested, and firefly/*Renilla* luciferase activity was determined using the manufacturer's protocol. Each transfection was performed in triplicate, and the experiments were repeated three times.

Quantitative Real Time PCR (qRT-PCR)—Total RNA was extracted using the RNeasy mini kit (Qiagen). Complementary DNA was synthesized from 2 μ g of total RNA using RevertAid fast strand cDNA synthesis kit (Thermo Scientific) according to the manufacturer's protocol followed by qRT-PCR using ABI-SYBR GREEN mix (ABI). qRT-PCR was performed using 7500 real time PCR machine. Primers used are listed in Table 2.

Microarray Analysis—Total cellular RNA was extracted, and RNA quality was determined using a Nanodrop spectrophotometer (NanoDrop Technologies, Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Samples with RNA Integrity number of greater than 7.0 were taken for Affymetrix Human Whole Genome Gene Chip (Human HT Prime View Gene Chip)-based microarray hybridization as per the manufacturer's recommended protocol (Affymetrix, Santa Clara, CA). Raw data were RMA (Robust Multiarray Average)-normalized, and baseline transformation was done to median of all samples using Gene Spring GX 12.5 software (Agilent Technologies).

Statistical Analysis of Differentially Expressed Genes from Microarray—Differentially expressed probe sets (genes) upon ZMYND8 siRNA treatment in comparison with control siRNA- treated cells were identified by applying a fold change threshold of absolute fold change greater than or equal to 1.1, and a statistically significant t test p value threshold was adjusted for the false discovery rate of less than or equal to 0.05. The same was visualized using a volcano plot to understand the differential expression pattern. Unsupervised hierarchical clustering of differentially expressed genes upon treatment in comparison with untreated were done using Euclidian algorithm with Centroid linkage rule to identify gene clusters whose expression levels are significantly reproduced across the replicates.

Biological Pathways and Gene Ontology Enrichment Analysis of Microarray Data—Differentially expressed gene list was subjected to biological significance analysis by GOElite tool. 21,887 protein coding genes were used as the background, and differentially expressed gene lists were used as query. The database of Gene Ontology categories, Wikipathways, KEGG Pathways, Pathway Commons, Pheno Ontology, Diseases, Protein Domains, transcription factor targets, and tissue expression was configured for significance analysis. Each query list was subjected to over-representation analysis against each of the above databases. A Z score and permutation or Fisher's Exact Test p value were calculated to assess over-representation of enriched biological categories.

Results

ZMYND8 Is a Histone H3/H4-interacting Protein—The human transcription factor ZMYND8 is a component of the transcription coregulator network having a wide range of interacting partners, including chromatin remodeling complexes and histone demethylase/deacetylase enzymes (5). It has been reported as a novel DNA damage response factor that recruits NuRD complex to damaged chromatin (23). Its involvement in chromatin template-dependent processes, *viz.* transcription and repair, prompted us to speculate that ZMYND8 could be a chromatin-associated protein. Indeed, we found that ZMYND8



TABLE 2

Primer list

Fw is forward, and Rv is reverse.

For gRT-PCR ZMIND/8 PV: 5'-CNG AAA ATG AAA CAG CCA GGC-3' TAU PV: 5'-CNG AAA TG AAA CAG CCA GGC-3' TAU PV: 5'-CNG CAG TG TG CAG TG TG CAG AGA -3' TUBB3 PV: 5'-CNG TAG TG TG CAG TG TG CAAA TG AAA CAG CCA GG CAG DRD2 PV: 5'-CNG TG CG TG TG CAAA TG TG CAAA TG AAA CAG CCA GG CAG DRD2 PV: 5'-CNG TAAA CCT TG CG CTT CT CAA T-3' DRD2 PV: 5'-CNG TG CG CG CTT CT CAAA TG 'TG' REST PV: 5'-CNG TTC CAG TG TA CCA CCA CG CAAA T-3' GAPDH PV: 5'-CNG TTC CAG TG TA CCA TC TTC CAC AAA T-3' PV: 5'-CNG TTC CAT TTC CAG TG TA CCA CCA CG CAAA T-3' PV: 5'-AAT CCC ATC CAC CAT CT CC CCA-3' BARDA PV: 5'-AAT CCC CAT CAC CC TT TG CGC TG CA-3' PV: 5'-AAT CCC ATC ACC CAT CAC CC CAAA CCA CC-3' PV: 5'-AAT CCC CAT CAC CAT CT CC CAA-3' BARDA PV: 5'-AAT CCC CAT CAC CC TT TG CGC TG CA-3' PV: 5'-AAT CCC CAT CAC CCCCCA-3' PV: 5'-AAT CCCCCTCTCTAAACCCCCCCA-3' BARDA PV: 5'-AATCACCCCCAA-3' WTSA PV: 5'-AATCACCCCCAA-3' PKB3 PV: 5'-CACACCCCCAA-3' WTDR13 PV: 5'-CACACCCCCAA-3' WTDR14 PV: 5'-CACACCCCCCAA-3' WTDR13 PV: 5'-CACACCCCCAACACCCC-3' WTDR14 PV: 5'-CACACCCCCAACACCC-3' WTDR13 PV: 5'-CACCCCCCCAACACCCC-3' WTSB1 PV: 5'-CACCCCCCCAACACCCC-3'	Gene name	Sequence
ZMYADB Pro: 5 '-CAC AAA ACC AC CCA GOG -3' TAU Pro: 5 '-CAC TAG CAA AC CAS CCA GOG -3' TAU Pro: 5 '-CAC TAG CAA AC CAS CGA AC-3' TUBB3 Pro: 5 '-CAC TAG CAT CAC CAA TAG TCT ACA A-3' TUBB3 Pro: 5 '-CAC AG TCT CAC AT TAG CCT AC CAA DRD2 Pro: 5 '-CAC TAG CAC TCT CAC CAAC TAG 'CT CC-3' DRD2 Pro: 5 '-CAC TAG CCT CACCAC ACT ACC CAC CAAA TCT ACC 'ACC '	For aRT-PCR	
TAU Pv: 5 '-ACT TTS CAT CAS CAS GAA AG-3' TUBB3 Pv: 5 '-GGA CAS TAS CAS AGA AGA TAS TTC AAA T-3' TUBB3 Pv: 5 '-GGA AGA TCT CAG CCT TC CAG T-3' DRD2 Pv: 5 '-GGA CAG CCA CCA CCT ACA TC3' REST Pv: 5 '-GGA CAG CCA CCA CCA TCT CC-3' REST Pv: 5 '-GGA CCA CCA CCA CCA TCT CC-3' GAPDH Pv: 5 '-GGA CCA CCA CCA CCA TCT CC-3' FV: 5 '-GGA CCA CCA CCA CCA CCA TCT CC-3' PV: 5 '-ACA CCA CCA CCA CCA CCA TCT CC-3' FEB Pv: 5 '-ACA CCC CT TTS GCT CCC-3' FEB Pv: 5 '-ACA CCA CCA CCA CCA CCA CCA CCA CCA CCA	ZMYND8	Fw: 5'-CAG AAA ATG AAA CAG CCA GGG-3'
TAU Pro: 5'-GG CGA GTO CAN TAG TOT ACA A-3' TUBB3 Pro: 5'-GG TA AGA GT TO CAN TAG TOT ACA A-3' TUBB3 Pro: 5'-GC TCA AGA GT TO CCT CCA CC-3' DRD2 Pro: 5'-GC TCA AGA TOT CCT CCA CC-3' DRD2 Pro: 5'-GC TCA AGA TOT CCT CCA CC-3' RST Fro: 5'-GC TOT CG GT TA CCA TOT GC CC3' GAPDH Pro: 5'-TCC TOT CG TOT TOT CCA-3' E2F3 Pro: 5'-TCC TOT CCCATCCCACA ACT 3C CAT GA CC-3' FEB Pro: 5'-TCC TOT CCCATCCACA ACT 3C CAT GA CC-3' HIPK3 Pro: 5'-ACTCCACAAGCCCCATCCCCACAGC BARPA Pro: 5'-ACTCCACAAGCCCCATCGCCCCACAGC HIPK3 Pro: 5'-ACTCCACACAGTCCTTACAGCCCCC-3' BARPA Pro: 5'-TCCCACTTACCACATCCCCCACAGC WDR13 Pro: 5'-ACTCCACACTTCCCCACAGC-3' WDR13 Pro: 5'-ACTCCACACTCCCCACAGCCCCA-3' WSB1 Pro: 5'-ACACCACTTCCCACAGCCCCAC-3' WSB1 Pro: 5'-CCACCTCCCACAGCCCCACAGCCCCAC-3' WFS1 Pro: 5'-CCACCTCCCACAGCCCCCACAGCCCCAC-3' WSB1 Pro: 5'-CCACCTCCCACAGCCCCCACAGCCCCAC-3' WFS1 Pro: 5'-CCACCTCCCACAGCCCCCACAGCCCCAC-3' WFS1 Pro: 5'-CCACCTCCCACAGCCCCCACAGCCCCAC-3' WFS1 Pro: 5'-CCACCTCCCACAGCCCCACAGCCCCAC-3'		Rv: 5'-ACT TTG CAT CAG CCA GGA AG-3'
TUBB3 Rv: 5'-COA AGG CTT CT GG CTT CA T-3' DRD2 Rv: 5'-COA AGG CTT CGC CCT CC-3' RV: 5'-COT AGA CTG CG CCT CAC ACT ACC TOA T-3' REST Rv: 5'-COT AGA CGC GTA TTG TAC AGC AT-3' GAPDH Rv: 5'-AGG CTT TTG GC CTT TTG CGC GTA CTA ACC AT-3' E2F3 Rv: 5'-AGT CCC CATT TTG GC CTT TTG CGG GTA CTA CC ATC ACC ATC AT	TAU	Fw: 5'-GCG GCA GTG TGC AAA TAG TCT ACA A-3'
TUBB3 Pwt 5'-CCC TCA ACA TCP CCC CC CC-3' DRD2 Pwt 5'-CCC TCA ACC TCP CCC CC-3' REST Fwt 5'-CCC TCA ACC TCP CCC CC-3' REST Fwt 5'-CCC TTC ACC CCCACA ACC TACC TAC T-3' GAPDH Fwt 5'-CCT TTC ACC TCP CCC CTA ACC TCAC -3' FEB Fwt 5'-ACC TCA TCP CCC CCT ACC -3' FEB Fwt 5'-AAC CCC TATC TCC ACC ACC -3' FEB Fwt 5'-AAC CCC TATC TCC ACC ACC -3' FEB Fwt 5'-AAC CCC TTC ACC ACC -3' FEB Fwt 5'-ACCCCACATCACCC-3' BMPRA Fwt 5'-ACCCCACATCACCCCCAC-3' HIPK3 Fwt 5'-ACCCACATCTCACACCCC-3' BARD1 Fwt 5'-ACCCACATCTCAACCCCCAC-3' WDR13 Fwt 5'-ACCCACATCTCAACACCCCAC-3' WDR13 Fwt 5'-ACCCACATCTCCAACACCCC-3' WCS1 Fwt 5'-ACCCACATCTCCAACACCCA-3' WTS1 Fwt 5'-ACCCACATCTCCAACACCCA-3' WS1 Fwt 5'-CCCCACATCCCAACACCCA-3' WDR13 Fwt 5'-CCCCACATCCCAACACCCA-3' WCS1 Fwt 5'-CCCCACAATCCCAACACCCA-3' WTS1 Fwt 5'-CCCCACAATCCCAACCCCAACACC-3' WTS1 Fwt 5'-CCCCCACAATCCCAACCCCAACACC-3' WTS1 Fwt 5'-CCCCCACAATCCCAACCCCAACCC-3' WTS1 Fwt 5'-CCCCCACAATCCCAACCCCACC-3' WTS1 Fwt 5'-CCCCCCAAATCCCCAACCCCAACACC-3' FWTS1 Fwt 5'-CCCCCCAAATCCCCAAC		rv: 5'-gga agg tca gct tgt ggg ttt caa t-3'
DRD2 Rv: 5'-COT ACA TC GC CCT CT CC-3' DRD3 Rv: 5'-COT ACA CC ACC ACC ACC ACC TAC T-3' REST Rv: 5'-CAG CT TC GC GT ACT ACC TG T-3' GADDH Rv: 5'-AGG TG TUT GG GT GT AGC ATT ACC AT-3' E2F3 Rv: 5'-AGG ACT TUT GG CT GT -3' TFEB Rv: 5'-AGT ACC TTT GG GT GT TC C-3' BMP8A Rv: 5'-AGT CCC TUT GG GT GT AGC ATT ACC A-3' HIFK3 Fv: 5'-AGT ACC CTTTTG GG TGT TCC-3' BARDI Fv: 5'-AGT CCCAAACGGTCCTTCTA-3' HIFK3 Fv: 5'-AGGCAACGTTGAACGC-3' BARDI Fv: 5'-GGCAACGTGAAGGTCCCTCAA-3' WDRJ3 Fv: 5'-GGCAACGTGGAAGGTCGTC-3' PK1 5'-AGGCAACGTTGAAGGCCCAACG-3' WDRJ3 Fv: 5'-GCCAACGTGGAAGGTGGA-3' Fv: 5'-GCGAGCTTGGAAGGCCCAACG-3' Fv: 5'-GCGAGCGTGGAGGTGG-3' WSSI Fv: 5'-CCCAGAGGCAGCAGGCGGAAGGCG-3' WFSI Fv: 5'-CCCAGAGGCGAAGGCGGAAGG-3' WSSI Fv: 5'-CCCTGCGGAAGCTGGGAGGCGGAAGGCGGAAGGCGAGGAGGGAG	TUBB3	Fw: 5'-GCC TCA AGA TGT CCT CCA CC-3'
DRD2 PW 5 -TGC CAG CCA CCACCA ACT ACC TO T-3' REST PW 5 -CAG CT CT TAG CCG TA TAG AGC AT-3' REST PW 5 -CAG CT CT TAG CC TAG TAG CAT -3' PW 5 -CCAT TC CAG CAT CACC ATC ACC ATC ATC AGC AT-3' PW 5 -CAT TC CCA TC ATC ATC AGC AT-3' PW 5 -AATROCCACCATCACACAATCCA-3' PW 5 -AATROCCACCATC AGC ATC ATC ATC AGC AT-3' PW 5 -AATROCCACCATTAGCCACACAATCCA-3' PW 5 -AATROCCACCATTAGCCACACAATCCA-3' PW 5 -AATROCCACCATTAGCCACACAATCCA-3' PW 5 -AATROCCACCATTAGCCACACAATCCACA' PW 5 -AATROCCACCATTAGCCACACAATCCACA' PW 5 -AATROCCACCACTTAGCACACACACACACACACACACACACACAC		Rv: 5'-CGT ACA TCT CGC CCT CTT CC-3'
REST FW: 5'-GAB CTO TAG COC CTA ACC ARC CAC-3' REST FW: 5'-GCT TTC GCT TAG ACC AT CCTC CAC-3' GAPDH FW: 5'-ART CCC ATC CAC CAC-3' E2F3 FW: 5'-ART CCC ATC CAC CAC-3' TFEB FW: 5'-ART CCCC ATC CACC CAC-3' BMP8A FW: 5'-ART CACCATCTTC CAC-3' HIPX3 FW: 5'-ART CACCATCTTC CAC-3' BARDI FW: 5'-CACCATARACCTCATCACC-3' JEARS ACC CACCATCTTCAAAACCGCC-3' FW: 5'-CACCATARAACCGCCATTCACAACCGC-3' BARDI FW: 5'-CACCATARAACCGCCAG-3' JEARS ACC CACCATCTCAAAACCGCC-3' FW: 5'-CACCATARAACCGCCAG-3' JEARS ACC CACCATCTCCAAACTCACGC-3' FW: 5'-CACCATARAACCGCCAG-3' JEARS ACC CACCATCTCCAAACTCACGCCAG-3' FW: 5'-CACCATARAACCGCCAGGACGCGCG-3' JEARS ACC CACCATCTCCAAACTCACGCCAG-3' FW: 5'-GACATCTCAACTCCAGAGACC-3' JEARS ACC CACCATCTCCAAACTCACGCCCAGGACGCGAATCACTC-3' FW: 5'-GCGATTCCTCAACCCCAAGGACGC-3' JEARS ACC CACCATCGCCCCCAGGACGACTCCCAC-3' FW: 5'-GCGATTCCCACCCCCAAGGACGC-3' JEARS ACC CACCATCGCCCCCCCCCCCCCCCCCCCCCCCCCCC	DRD2	Fw: 5'-TGC AGA CCA CCACCA ACT ACC TGA T-3'
RESJ FW1 5CCT TPC GQT TPC A GC CAT GC-3' GAPDH FW1 5'-ART CCC ATC CAC ATC ATC TPC CAG-3' E2F3 FW1 5'-ART CCC CATC CAC CATC ATC CAG-3' TFEB FW1 5'-ART CCCCCTATACCCCCTTCTAG-3' BMP8A FW1 5'-ART CCCCTTCTAGCTCCGATACCCC-3' HIPK3 FW1 5'-ART CCCCTTCTAGCTCCGATACCCC-3' BARD1 FW1 5'-ACAGTCCCCCATACCCC-3' BARD1 FW1 5'-ACAGTCCCTTCTAGCTTCTCTCAG-3' BARD1 FW1 5'-ACAGTCCCTCTATACCCC-3' BARD1 FW1 5'-ACAGTCCTCCTATACCCC-3' WDR13 FW1 5'-ACAGTCCTACCTTCTAGCAGCTCCCGA-3' WDR13 FW1 5'-ACCCTAACCCCATCTCTAGCCC-3' WSB1 FW1 5'-CCCTAACCCATCGACTAGCCC-3' WSB1 FW1 5'-CCCTAACCCATCGACTAGCCC-3' WFS1 FW1 5'-CCCTACAGCGACTGCACTGCACGC-3' WFS1 FW1 5'-CCCACAGCCACGCATGCACGCCCCCC-3' WFS1 FW1 5'-CCCACAGCCACGCACCCCCCCC-3' WFS1 FW1 5'-CCCTCCCCACGCCCCCCAGG-3' WFS1 FW1 5'-CCCCACCCCCCCCCCCCCCC-3' FW2 5'-CCCCACCCCCCCCCCCCCCC		Rv: 5'-GAG CTG TAG CGC GTA TTG TAC AGC AT-3'
GAPDH RV 5. 5-AAT CCC AT CAC AC THE UP OF 01-3' E2F3 RV 5-AAT CCC TT THE CCT CAC-3' E2F3 RV 5-AATACCCCTT THE GCT CCC-3' TFEB RV 5-AATACCCCTACACACCCGTCCCC-3' BMP8A RV 5-ACCACTCACAAACCGTCCCTTCAC-3' HIPK3 RV 5-CONTRACACTCGTACAC-3' BARDI RV 5-CONTRACACTCGTCACC-3' BARDI RV 5-AATACCCCAAACCGCCCCCA-3' BARDI RV 5-CONTRACACTCGTCACC-3' BARDI RV 5-AATACCCCAAACCGCCCCCA-3' BARDI RV 5-CONTRACACTCGTCACC-3' WDR13 RV 5-AATACCCCAAACCGCCC-3' WDR13 RV 5-CONTRACACTCCAAACCGCC-3' WDR14 RV 5-CONTRACACCAACCGCAC-3' WSB1 RV 5-CONTRACACCAACCGCA-3' WSB1 RV 5-CONTRACACCAACCGCACCGCA-3' WTS1 RV 5-CONTRACACCCAACCGCA-3' WTS1 RV 5-CONTRACACCAACCGCACCGC-3' WTS1 RV 5-CONTRACACCCAACCGCCCCC-3' WTS1 RV 5-CONTRACACCAACCGCACGCA-3' WTS1 RV 5-CONTRACACCGCAACCGC-3' WTS1 RV 5-CONTRACACCGCAACGCA-3' WTS1 RV 5-CONTRACACCGCAACGCA-3' RV 5-CONTRACCCCAAACCCCAACCA-3' RV 5-CONTRACCCGCAACCGCA-3' <t< td=""><td>REST</td><td>Fw: 5'-CCT TTC GCT GTA AGC CAT GC-3'</td></t<>	REST	Fw: 5'-CCT TTC GCT GTA AGC CAT GC-3'
GAPDA FW 5 -AART ACC CTA TTG GCT CCC-3' E2F3 FW 5 -AART ACC CTA TTG GCT CCC-3' FFB FW 5 -AARTACCCTAACGCCGTTCC-3' BMP8A FW 5 -AARTACCCAACAGCCCCTTCC-3' HIPK3 FW 5 -AARTACCACAACGCCCTTCCAC-3' BARD1 FW 5 -AARTACCACATCAACGCCCCCAC-3' BARD1 FW 5 -AARTACCACATCAACGCCCCCCCCCCCCC-3' ZNF687 FW 5 -AARTACCACATCAACGCCCCCCCCCCCCCCCCCCCCCCCC	CADDH	RV: 5'-TGG TGT TTC AGG TGT GCT GT-3'
E2F3 Product of the first of th	GAPDH	FW: 5 -AAT CCC ATC ACC ATC TTC CAG-5
Lab 3 Rev 5 F-AGTICACAAAGGGTCCTTURA-3' TFEB Fw 5 F-AGTICACAATCGCTCGTAAGCT3' BMP8A Fw 5 FrochagGCTCCTGTAACC-3' HIRK3 Fw 5 FrocCAGTATCACGTTCGTCAAC-3' HIRK3 Fw 5 FrocCAGTATCACGTTCGTCAAC-3' BARD1 Fw 5 FrocCAGTATCGACGTTCGTCAACCGC-3' BARD1 Fw 5 FrocCAGTTCGTGAAGGCCCGA-3' WDR13 Fw 5 FrocCAGTTCGTAAGGCCGACGA' WDR13 Fw 5 FrocCAGTTGCGAGGGCGACGAGACGGACGAGCA' VSB1 Fw 5 FrocCAGTGCGAGGGACGGACGACGACGA' WFS1 Fw 5 FrocCAGTGTGCGCGCCGACG' WFS1 Fw 5 FrocCAGGGGAGGGACGGACGCGACG' WFS1 Fw 5 FrocCAGTGTGCGGCCCCCCGCG-3' BTG1 Fw 5 FrocCAGGGGGGGGGGGGGGCCGACGCCCCCCGC-3' KE2B Fw 5 FrocCCAGTCTTCTGCGGCGCCCCCCCCCCCCCCCCCCCCCCC	F2F2	RV: 5-ATG ACC CTT TTG GCT CCC-5
TFEB FP: 5'-ACCASTRCACCECATICAGETCOCCALTERAC-3' BMP8A FV: 5'-TEGETERACACTTEGAGETCOTCAC-3' BMP8A FV: 5'-TEGETERACACTTEGAGETCOTCAC-3' HIRK3 FV: 5'-TEGETERACCETTEGAACCG-3' BARD1 FV: 5'-ACACAGATTCTATATECCACCG-3' BARD1 FV: 5'-ATECCAETTEGAAGETCACC-3' BARD1 FV: 5'-ATECCAETTEGAAGETCACC-3' VDR13 FV: 5'-ATECCAEGETTEGAAGETCACG-3' VDR13 FV: 5'-ATECCAEGETTEGAAGETCACG-3' PEGF6 FV: 5'-ATECCAEGETTEGAAGETCACG-3' VDR13 FV: 5'-ATECCAEGETTEGAAGETCACG-3' VDR13 FV: 5'-ATECCAEGETTEGAAGETCACGGA' VSB1 FV: 5'-ATECCAEGETTEGAAGETCACGGA' VFS1 FV: 5'-ATECCAEGETTEGAACTEGEGGAA' VFS1 FV: 5'-ATECCAEGETTEGAAGETCACGGA' VFS1 FV: 5'-ATECCAEGETTEGAACTEGEGGAA' VFS1 FV: 5'-ATECCAEGETTEGTEACGACGA' VFS1 FV: 5'-ATECCAEGETTEGACTEGETGACGA' VFS1 FV: 5'-ATECCAAGETCACCCAAGEAA' VFS1 FV: 5'-ATECCAAGETCACCCAAG	1215	F_{W} . $5' = AGTTCACAAACCCGCTCCTAC=3'$
BMP8A Fri 5'-TOGTCATCAGCTTCAGCATTCAGCTG-3' BMP8A Fri 5'-TOGTCATCAGCAGCTTCATCAGCTG-3' HIPK3 Fri 5'-AACCAGCATTCATATCCG-2' HIPK3 Fri 5'-AACCAGCATTCATATCCG-2' BARD1 Fri 5'-AACCAGCATTCATATCGCCAG-3' ZNF687 Fri 5'-AACCAGCATTCATCAGCAGCGCCAG-3' WDR13 Fri 5'-AACGAGCACTGCG-3' WDR13 Fri 5'-AACGACGACGCGCGCGCGCGCGCGCGCGCGCGCGCGCGC	TFEB	Fw: 5'-AACAGTGCTCCCAATAGCC-3'
BMP8A Fy: 5'-TOGGCATCGTCGTCALC-3' HIPK3 Fy: 5'-TOGGCATCGTTGGTCGCCCA-3' HIPK3 Fy: 5'-ATCCACTCTTGGTCGCCCC-3' BARD1 Fy: 5'-TTGGATGCTCGGCCCCA-3' BARD1 Fy: 5'-TTGGATGCTCGGCCCCA-3' ZNF687 Fy: 5'-TTGGATGCCCCAC-3' WDR13 Fy: 5'-TTGGATGGCACGCGTC-3' PCGF6 Fy: 5'-TTGGATGGCACGCCTG-3' PBX1 Fy: 5'-TTGGATGGCACGCGTG-3' WSB1 Fy: 5'-TTGGATGGCACGCGTG-3' WTS1 Fy: 5'-TTGGTGGATTGGCTGGTG-3' WTS1 Fy: 5'-TGGATGGCACGCGCTG-3' WTS1 Fy: 5'-TGGATGGCACGCGCTG-3' WTS1 Fy: 5'-TGCCAGGATTGGCGCAG-3' WTS1 Fy: 5'-GGGATTGCCAGATTGGCAGGATGGA' WTS1 Fy: 5'-GGGATTGCCAGATTGGCAGGA-3' WTS1 Fy: 5'-GGGATTGCCAGGATTGGCGAGA-3' BTG1 Fy: 5'-GGGATTGCAGCCAGA-3' KIF2B Fy: 5'-GGGATTGCAGGGCTTTGCCAG' ZPP3 Fy: 5'-GGGGGTCCCGAGAGCCTGGTGC-3' ZMYND8 (human promoter) Fy: 5'-GGGGGTCCCGAGAGCTGGGACCCGACAGAGCCCGA' KiF2B Fy: 5'-GGGGGTCCCGAGAGCTGGGGCCCACAGAGCCGACCAGCGACCGAC	1120	Rv: 5'-TGCTGTACACATTCAGGTGG-3'
HIPK3 Fv: 5'-GGGCACCTTGTAAATCCG-3' HIPK3 Fv: 5'-ACCCACGATTCCATATCCGACGC-3' BARD1 Fv: 5'-ATCCCACGTTGGATGTCCCACG-3' BARD1 Fv: 5'-GGATTCCATGGACGCCCCG-3' ZNF687 Fv: 5'-AAAGGCAGAGGCACAGGCAGAGCCG-3' WDR13 Fv: 5'-AAAGGCAGAGGCACAGGACGAGACGCGACGAGAGCG-3' PCGF6 Fv: 5'-CTCTAAGGGAATCCGACGTGG-3' PK5 S'-CTCTAAGGGAATCCGACGTCGG-3' PK5 S'-CTCTAAGGGAATCCGACGGAGGAGCGACGACGCGAGAGGAGGAGGAGGAGGA	BMP8A	Fw: 5'-TGGTCATGAGCTTCGTCAAC-3'
HIR3Fr: 5'-ACCAGATTCTATATOCCAGC-3'BARD1Fr: 5'-TGGAATCCCACTCTGTAGGCCCAG-3'BARD1Fr: 5'-TGGAATCCCACGTCCCAAGAACTCAG-3'ZNF687Fr: 5'-ATGCAGCTCCCAAGCTACGACTCGG-3'WDR13Fr: 5'-TGGAAGCCGAGGCACAGCGC-3'PCGF6Fr: 5'-CTGGGAACCGACGTCCGACGTGCGAGGCGACGCGACGCG		Rv: 5'-TGGGCACCTTGTAAATCCG-3'
BARD1 FV = 5'-ATTCCACTCTTGATGCCCAG-3' BARD1 FV = 5'-AGCCTTCTACGAGGCTCGG-3' ZNF687 FV = 5'-AGCCTGCTTCCACGAGGCTCGG-3' WDR13 FV = 5'-AGGGGCGGACCTAGGACCGGGC-3' WDR13 FV = 5'-CTGGAAGGGCACGACCTGGATC-3' PCGF6 FV = 5'-CTCTAGGGGAATCCGACGCTG-3' PX51 FV = 5'-CTCTAGGGGAATCCGACGCTG-3' WSB1 FV = 5'-CTCTAGGGAACTCGCACGCTG-3' WSB1 FV = 5'-CACCAAGGCACAAGCTCGACG-3' WFS1 FV = 5'-CGCAAGGCCACAAGCTCGACG-3' WFS1 FV = 5'-CGCAAGGCCAAGCTCCACACG-3' HTR3A FV = 5'-CGCAAGCCCAAGCTCGCACG-3' BTG1 FV = 5'-CGCACATCCTTTCTCCGCC-3' KIF2B FV = 5'-CGCACACCACGCGGGGGATTAG-3' FV = 5'-CGCACTCTTTCTCCCCC-3' FV = 5'-CGCACTCTTTCTCCCCC-3' KIF2B FV = 5'-CGCACTCTTTCTCCCCC-3' KIF2B FV = 5'-CGCGGTTACCGAGGCTTGTCCTCCC-3' ZHP3 FV = 5'-GGCGTTCCGCACGGAGCCCCAACAATCCAC-3' KV = 5'-CGCTCGCACCCCACGGAGCCCCAACAAATCCAC-3' FV = 5'-CGCCTCGCACCCAACCAAATCCAC-3' ZMYND8 (human promoter) FV = 5'-GGGGTACCGGAGCCCCAACAAATCCAC-3' KV = 5'-CCCTCCACTAGCGACCCCCAACCAAATCCAC-3' FV = 5'-CCCCCCCCACCACACAAATCCACAC-3' ZMYND8 (human promoter with RARE mut) <td>HIPK3</td> <td>Fw: 5'-ACACAGATTCTATATGCCAGCC-3'</td>	HIPK3	Fw: 5'-ACACAGATTCTATATGCCAGCC-3'
BARD1 Fy: 5'-TGAAATTCCTGAAGGTCCACG-3' ZNF687 Fy: 5'-ATCCCAGGTTCCTACTGAGGTCCCAGG-3' WDR13 Rv: 5'-ATGCAGGGACCTGCAAGCCGA-3' WDR13 Fy: 5'-TGGAAGGGACGGAACTAGATC-3' PCGF6 Fy: 5'-CTCTGGAAGCGGACTGGATCGA-3' PX5 5'-TTGGTGGAAGCGGAACGCGGGACTAGATC-3' PK1 Fy: 5'-CTCTGGAAGCGGATGGGATGG-3' WSB1 Fy: 5'-CACGAGGACTCGACGCACGGACGGAGGACG-3' WFS1 Fy: 5'-CACAGAGCACTCCCAG-3' WTS1 Fy: 5'-CACCAAGGACTCCCAG-3' HTR3A Fy: 5'-CACCATCTACCACCC-3' BTG1 Fy: 5'-CACACCTCTCCAGGGATTGGGATGG-3' BTG1 Fy: 5'-CACCCCAAGCCCTACCCCAGG-3' BTG1 Fy: 5'-CACCCCAAGGGATTTCCCCTTTCTGCCCCAG-3' BTG1 Fy: 5'-CACCCCAAGCGATTCCCCTTTCTGCCCCAG-3' BTG1 Fy: 5'-CACCCCAAGCGATTCCCCTTCTTCTGCCCCAG-3' BTG1 Fy: 5'-CCCTCCCAAGCGTTTCTCTCTCTCCCCCAG-3' RtF2B Fy: 5'-TCCTTCTAGGAGCCTTTCCAGGCCCCACGA-3' RtF2B Fy: 5'-CCCTCCCACATCTACGCAGGCCC-3' RtF2B Fy: 5'-CCCTCCCACATCTCCAGGCTCCCCCCCCCCCCCCCCCCC		Rv: 5'-ATTCCACTCTTGATGCCCAG-3'
Rv:5'-GGCTTTCTACTCAGGATCTGG-3'ZNF687Fv:WDR13Fv:WDR13Fv:PCGF6Fv:S'-TGGAGGACGAGATCGATCGATCGA'PBX1Fv:S'-GGAGCATCGACGCGACTCGACTGA'WSB1Fv:S'-CCAAACCCAAACCCAGAGATCGACGAGA'WFS1FraccaAacCCCAAAGCCAGAGA'WTS1Fv:S'-CCACAAAGCCAAACCCCACAGA'HTR3AFv:S'-CCACACCCCACAACCCCAGAGA'BTG1Fv:S'-CCACACTCCCACAGATCGCACGA'BTG1Fv:S'-CCACACTCCCCACAGA'BTG1Fv:S'-CCACACTCCCCACGAGATCGAC'BTG1Fv:S'-CCACACCCACCCAGCAGA'BTG3Fv:S'-CCCACCCCCCCCCCCCAGAGATCGCC'KIF2BFv:For cloningZMYND8 (human promoter)Fv:For CoccCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	BARD1	Fw: 5'-TGAAATTCCTGAAGGTCCACG-3'
ZNF687 FW: 5'-ATCCCACCTTCCAAATCAG-3' WDR13 FW: 5'-CTGTGAAGGGACGAGGACTAAGC-3' WDR13 FW: 5'-CTGTGAAGGCACGAACTAGATC-3' PCGF6 FW: 5'-CTGTGAAGCACGTCCTG-3' PBX1 FW: 5'-CTGTGAAGCACGTCCGA-3' WSB1 FW: 5'-GGGTGCTGAGATTGCAGGACTG-3' WSB1 FW: 5'-GGGTGCTGAGATTGCAGACTGCAAC-3' WFS1 FW: 5'-GGCATCCAACACCCCAACA-3' HTR3A FW: 5'-CCCACAAGCACCCACAC-3' CD47 FW: 5'-GCGATTCCTTTCCCCCAGC-3' BTG1 FW: 5'-CCCACACGCGAACTACGACC-3' KIF2B FW: 5'-TCCAAGCGTAACCCCAACGAGGATTAG-3' FW: 5'-TCCACACGCGAGATTAG-3' FW: 5'-GCGATTCCCACCTTTCCTCCCCAC-3' KIF2B FW: 5'-CCACCACACGCAGGATTAG-3' FV: 5'-TCCCAACGCGAGGATTAG-3' FW: 5'-TCCCAACGCGGAGATTAG-3' ZFP3 FV: 5'-TCCCAACGCAGGATTAGC-3' ZMYND8 (human promoter) FW: 5'-GCGGTACCCGGAGCCCCAACAATCAG-3' RV: 5'-GGGGGTACCCGGAGCCCCCAACAATCAG-3' FV: 5'-GGGGGTACCCGGAGCCCCCAACAATCAG-3' ZMYND8 (human promoter) FW: 5'-GGGGGTACCCGGAGCCCCCAACAATCAG-3' RV: 5'-CCCTCCCACTAGGCGATCCTCTCTCTCTCCACGAGC-3' FV: 5'-GGGGGTACCCGGAGCCCCAACAAATCAG-3' ZMYND8 (human promoter with RARE mut) FV: 5'-GGCGGGCCCCAACCAACAAAACA-3'		Rv: 5'-GGCTTTCTACTGAGGATCTGG-3'
WDR13Rv:5' -AAAGAGCAGAGCAAGACG-3'WDR13Rv:5' -CTGGAGACCGAACTGATC-3'PCGF6Rv:5' -CTGTGAGATCCGACTG-3'PBX1Rv:5' -TTTGGTGGATCCGACTGC-3'WSB1Rv:5' -CTGCAGGCACGCACAC-3'WFS1Fw:5' -CTCCACAGGACATCGACCGCACAC-3'HTR3AFw:5' -CCCAACGACATCACCCCTAGC-3'CD47Fw:5' -CCACACGACATCGACCCCAC-3'BTG1Fw:5' -CCCACACGACTTCTTCCCCCAC-3'KIF2BFw:5' -CCCACCACGCCCCAACGCCCCACC-3'KIF2BFw:5' -CCCACCCCCAGGCTTCTCCCC-3'For cloningFw:5' -CCGGCTTCCCCCACCACGC-3'ZMYND8 (human promoter)Fw:5' -GGGGTCCCCCGGCCCCCACCACGC-3'Zmynd8 (mouse promoter with RARE mut)Fw:5' -GGGAGCCCGGCTTCCTCCCCAGC-3'KW:5' -GGGAGCCCCGACCCCCGCGCCCCCCCCCCCCCCCCACGACG	ZNF687	Fw: 5'-ATCCCAGCTTCCAAACTCAG-3'
WDR13 FW: 5'-TCGGAGGACGGAACTAGANCC-3' PCGF6 FW: 5'-CTCGTAAGGAAAACCTGGACGTG-3' PBX1 FW: 5'-ATGGTGAGATCGAGCCGATGG-3' PBX1 FW: 5'-AAAGGAAATCGAGCCACG-3' WSB1 FW: 5'-CCCATAGGAAATCCAGCAATGGAATCGACCCAG-3' WFS1 FW: 5'-ACCCAAAGGAATCGACCCAG-3' WFS1 FV: 5'-ACCCAAAGGAATCCCACG-3' HTR3A FV: 5'-CCCAAAGCAAACTTCCCCGCAGA-3' CD47 FV: 5'-CGGATTCACACTTCCCGC-3' BTG1 FV: 5'-CCCACCACGGAGGATATGG-3' KIF2B FV: 5'-CCCACCACGGAGGATATAG-3' ZFP3 FV: 5'-CCCCCCACTCTTTCCCGC-3' FW: 5'-GGGATTCACACGGAGGATATAG-3' FV: 5'-CCCATCCACACGGCAGGATACAACGGAGGATACGACGAGGAGAAGAACGACGGAGGATACGACGAGAAACGACGAACGA		Rv: 5'-AAAGAGCAGAGGACAAGACG-3'
PCGF6 Fw: 5'-CICITGAAGGAATGCGACGCAG-3' PBX1 Fv: 5'-TTTGGGGAGATGCAGTCCGAG-3' WSB1 Fv: 5'-GGGTTCCTGAGATGGAATGAGATGGAATGAGAGAGAGAGA	WDR13	Fw: 5'-TGGAAGGGACGGAACTAGATC-3'
PCOP0 PW: 5 '-CTUTAGGGAARATCCAGTCCTG-3' PBX1 PW: 5'-AAAGGACATTCGACAGTCCG-3' PBX1 PW: 5'-AAAGGACATTCGACAGTCGG-3' WSB1 FW: 5'-CTCACAAGGACATCGCACAG-3' WFS1 FW: 5'-CTCACAAGGTCATCCCAGC-3' HTR3A FV: 5'-CGCACTACAAGTCCCCAGC-3' CD47 FW: 5'-CGCACTTCTTTTCTGCCCCAG-3' BTG1 FW: 5'-TCCCACACAGGTTCCCCGC-3' KIF2B FV: 5'-TCGGAATACCACCCCCAGG-3' KIF2B FW: 5'-TCGTGAGATCCCCCC-3' FP3 FW: 5'-TCGGAATACCACCCC-3' For cloning FW: 5'-TCGTGAGACCCCCCAACAACCCC-3' ZMYND8 (human promoter) FW: 5'-GGGGTACCGGAGCCCCAACCAATCCAG-3' FW 5'-GGGGTACCGGAGCCCCCAACCAATCCAGC-3' ZMYND8 (human promoter) FW: 5'-GGGGTACCGGACCCCCCAACCAATCCAGC-3' FW 5'-GGGGTACCGGACCCCCAACCAATCCAGC-3' ZMYND8 (human promoter) FW: 5'-GGGGTACCGGACCCCCAACCAATCCAGC-3' FW 5'-GGGGGTACCCGGACCCCCAACCAACCAGAC-3' ZMYND8 (human promoter) FW: 5'-GCGCCTCTACCCCGATCCTAACCCGACCCCAACCAACCAGAC-3' FW 5'-GCGCCCCCCCCCCCCCCACCGACCCCAAACCAGAC-3' ZMYND8 (human promoter with RARE mut) FW: 5'-CCTTTGTAGCCCCGGCTTCACGAGGCC-3' FW 5'-CCCTTTGCTAACCCGGCTTACCGGCT	DCCF	RV: 5 - CTGTGGAAACGTTGGTGTG-3
PBX1 FW: 5'-AAAGGACATTGACCGGATGC-3' WSB1 FW: 5'-GGTTGCTGACATTGACCGACGC-3' WFS1 FW: 5'-ACCCAAAGCCACACA-3' WFS1 FV: 5'-ACCCAAAGCCCAACCCCACACA-3' WFS1 FV: 5'-GCACTCACCACACCCCACAA-3' HTR3A FV: 5'-GCACTTACAACTTCCCCTTGC-3' CD47 FV: 5'-GCACATCACCCAAGGATAGCAG-3' BTG1 FV: 5'-CCACCAACGGACGCCAG-3' KIF2B FV: 5'-GCCACACCACGGAGATATAG-3' ZFP3 FV: 5'-GCGCATTCACCTTTCCCCGC-3' ZFP3 FV: 5'-GCGATTCACCGTAGCCGAGGATATAG-3' ZMYND8 (human promoter) FV: 5'-GCGGGTACCGGAGCCCCAACAATCCAGC-3' Zmynd8 (mouse promoter with RARE mut) FV: 5'-GCCACCCCTTAGCCGACCCGACCCTAACAGGC-3' ZMYND8 (human promoter with RARE mut) FV: 5'-GCCTTCTCTCTCTCTCTCTCTCAACGGC-3' ZMYND8 (human promoter with RARE mut) FV: 5'-GCCACCCCCGAGCCTAACCAAAACCAAA-3' FV: 5'-GCTTTGTTCTCTCTCTCTCTCTCTCTAACAAAA-3' FV: 5'-GCCACCCCCGAGCCTAACCAAAACCAAA-3'	PCGF0	FW: 5 -CTCTAAGGGAAATCCGACGTG-3
I DAT I'W 5 '-AGGETTGCTGAGATGGAATAG-3' WSB1 Fw: 5'-CGCAAGGCACTCGAAGACGCACG-3' WFS1 Fv: 5'-CGCAAAGCAAGACTCCAAGC-3' WTR3A Fw: 5'-CGGATTCCACCCTAAGCCCAAGA-3' CD47 Fw: 5'-CGGATTCCACTCTTTTCGGC-3' BTG1 Fv: 5'-CCACACAGGCTTCACCCCCAGGATAG-3' KIF2B Fw: 5'-TCACCACAGGGTAACCCC3' ZFP3 Fw: 5'-CGGGTTCTCTCTCCCCTCGC-3' Fw: 5'-CCCACCCAGGGTAACCCC-3' Fw: 5'-TGCTACAACTTCTTTCGGC-3' ZMYND8 (human promoter) Fw: 5'-GGGGTTACCGGAGCCCCAACAAATCAAGC-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-CCCTTCCTAGACTCCGAGCCCCAACAAACAAGA-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-CTCTTTTAGGTCGAGCTTAGGCG-3' Fw: 5'-CTCTTTAGGCTCGAGCCTAACCCAGAC-3' Fw: 5'-CTCTTTAGGCTTAGGCCTAGGCG-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-CTCTTTAGGCTCGGAGCTCTAAGCAAGA-3' Fw: 5'-CTCTTTAGGCTCGAGCCTAACCAAGA-3' Fw: 5'-CTCTTTAGGCTCGAGCTAAGACA-3'	PRX1	F_{W} , $5'_{-\lambda\lambda}$
WSB1Fw5'-TCACAAGGACATCGCACAG-3'WFS1Fw5'-ACCCAAAGCAAGACTCCAG-3'WFS1Fw5'-ACCCAAAGCTAACCCAAGA-3'HTR3AFw5'-GACATCTACACTTCCCCTGG-3'CD47Fw5'-ACCCAACCACAGGAGATATAG-3'BTG1Fw5'-TCATCCACAGGTATCCCGC-3'KIF2BFw5'-TCGTTGCAGAGGTTATGCATCCAGG-3'ZFP3Fw5'-TCGTTGCGAGGTTGTCCCGG-3'For cloningFw5'-CCATCTCCACTCTCCCCTCTCCTCGC-3'ZMYND8 (human promoter)Fw5'-GGGGTACCGGAGCCCCAACAAATCAG-3'ZMYND8 (human promoter with RARE mut)Fw5'-GGGGGTACCGGGTTACCAGAGA-3'ZMYND8 (human promoter with RARE mut)Fw5'-CCCTTCGTTAGCGCTTAGCGCTTAGCAGAGA-3'Fw5'-GCCCTTGCCATCTAGGGCTGGGGTGC-3'ZMYND8 (human promoter with RARE mut)Fw5'-GCCCTTGCTAGCCCTAACGAGA-3'Fw5'-GCCCCCCTAAGCCCGAGCCTAACAAGA-3'ZMYND8 (human promoter with RARE mut)Fw5'-CCCTTGCTAACCGGGTTAGCCAAGAC-3'FW5'-CCCTTGCTTAGCGCTTAGCGCTTAGCAGC-3'ZMYND8 (human promoter with RARE mut)Fw5'-CCTTGCTAACCGGGTTAGCCAAGCC-3'FW5'-CCTTGTTTAGGCTCGGGTTAGCGAGCCTAACAAGA-3'ZMYND8 (human promoter with RARE mut)Fw5'-CCTTGCTAACCCGAGCCTAACAAGA-3'FW5'-CCTTGCTTAGCTCTAACCGGGTTAGCCAAGCC-3'FW5'-CCTTGTTTAGGCTCGGGTTACCAAGAC-3'FW5'-CCTTGCTTGTAAGCCCGAGCCTAACAAGA-3'FW5'-CCTTGCTTGTAAGCCCGAGCCTAACAAGC-3'FW5'-CCTTGCTTGCTAACCAAGCC-3'	IBAI	$R_{\rm W}$: 5'-GGGTTGCTGAGATGGGAATAG-3'
Rv:5' - ACCCAAAAGCAAGACTCCAG-3'WFS1Fw:5' - GCAAGCTCCAACCCCAAGAA-3'Rv:5' - TCTCCACAAAGTCATCCAGC-3'HTR3AFw:5' - GGCATCTACAACTTCCCCTTCG-3'CD47Fw:5' - CGACATCTACAACTTCCCCAG-3'BTG1Fw:5' - CCAACCACAGCAGGATATAG-3'KIF2BFw:5' - TCGTTCGAGGTAACCGAGGTACCC-3'KIF2BFw:5' - TCGTTGGAGCTTTGCTCC-3'ZFP3Fw:5' - GGGGTACCGGAGCCCAACAAATCCAG-3'Rv:5' - CCAACCGAGCCCGGAGCCCCACAAATCCAG-3'Rv:5' - CCATCTGCCAGGTGCGGTXMYND8 (human promoter)Fw:S' - GGGGGTACCGGAACCCCAGGCCCCAACGAA-3'Zmynd8 (mouse promoter with RARE mut)Fw:S' - GCCCCCCCAAGACCCGAGCCCCAACAAAGG-3'Rv:5' - CCTCTTTTTAGGCGCTAAGGGGTGGC-3'ZMYND8 (human promoter with RARE mut)Fw:S' - CCTCTCTGCTACCCGAGCCCCAACAAAGC-3'Rv:5' - CCTCTTTTAGGCTCGCGCTAAGCGGTGGCG-3'Rv:5' - CCTCTTTTAGGCCCCCCCCAAGCAAAGC-3'Rv:5' - CCTCTTTTAGGCCCCCCCCAAGCAAAGC-3'Rv:5' - CCTCTTTTAGGCCCCCCCCAAGCAAAGC-3'Rv:5' - CCTTTTTAGGCCCCCCCCAAGCCCAACAAAGC-3'Rv:5' - CCTCTTTTAGGCCCCGAGCCTAACAAAGC-3'Rv:5' - CCTTTTTAGCACCCGAGCTAACCAAAGC-3'Rv:5' - CCTTTTTAGCACCCGAGCTCAACAAAGC-3'Rv:5' - CCTTTTTAGCACCCGAGCTAACCAAAGC-3'	WSB1	Fw: 5'-TCACAAGGACATCGCACAG-3'
WFS1 Fw: 5'-GGAAGCTCAACCCCAAGA-3' RV: 5'-TCTCCACAAAGTCATCCCGC-3' HTR3A Fw: 5'-GGATTCACCTTTCCGC-3' RV: 5'-CGGATTCACCTTTCCGGC-3' CD47 Fw: 5'-AGCCATTCTTTTCGTCCAG-3' BTG1 RV: 5'-CCAACCACGGGGATATAG-3' RV: 5'-TCGCAATTCTCCCGC-3' KIF2B Fw: 5'-TGCGAATACAACGGTAACC-3' RV: 5'-TCGTATGGAGGCTTGTCACCGA' RV: 5'-TCGTAGGAGGCTTGTCACC-3' KIF2B Fw: 5'-TGGTATGGAGGCTTGTCACC-3' RV: 5'-CCCTCCACTAGGAGGCC-3' ZFP3 Fw: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' RV: 5'-CCCTCCACTAGGCTGGTG-3' RV: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' RV: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' RV: 5'-GGGGTACCGGAGCTCCTGCTCTCTCTCTCTCTCTCTCTCT		Rv: 5'-ACCCAAAAGCAAGACTCCAG-3'
Rv:5'-TCTCCACAAAGTCATCCAGC-3'HTR3AFw:5'-GCACTCTACAACTTCCCCTTCG-3'CD47Fw:5'-AGCATTTACACTTTTCGCCAG-3'BTG1Fw:5'-CCAACCACAGCGAGGATATAG-3'RV:5'-TCATCTCCCAACGTACCCC-3'RV:5'-TCGCATATCAACGTTACCCC-3'KIF2BFw:5'-TGGTTATGGTGCATGAGTCC-3'ZFP3Fw:5'-CCCTCGCATACCAGGAGGCTTGTCATC-3'For cloningFw:5'-GGGGTACCGGAGCCCCAACAAATCAG-3'ZMYND8 (human promoter)Fw:5'-GGGGTACCGGAGCCCCAACAAATCAG-3'Rv:5'-GGGGGTACCGGAGCTCTGCGCTTCTCACAGAAA-3'ZMYND8 (human promoter with RARE mut)Fw:5'-GCCCCTAACCCGAGCCCTAACAAAA-3'Fw:5'-GCCCCCTAACCCGAGCCCTAACAAAAA-3'Rv:5'-GCCCCCTAACCCGAGCCTAAGGGCGCC-3'Rv:5'-GCCACCCCTAAGCCGATCCTAAGAAA-3'Fw:5'-GCCCCCCCTAAGCCGATCCTAAGAAA-3'Fw:5'-GCCCCCCAACACAAAACAA-3'Fw:5'-GCCACCCCTAAGCCGATCCTAAAAAA-3'Fw:5'-GCCCCCCAACCACAAAACAAA-3'Fw:5'-GCCCCCCAACCACAAAACAAA-3'Fw:5'-GCCACCCCTAAACCCGACCCTAACAAAA-3'Fw:5'-GCCACCCCTAAGCCGATCCTAAAAAA-3'Fw:5'-GCCACCCCTAAACCCAAAC-3'Fw:5'-GCCACCCCTAACCCGACCCTAACAAAA-3'Fw:5'-GCCACCCCTAACCCGACCCTAACAAAA-3'Fw:5'-GCCACCCCTAACCCGACCCTAACAAAA-3'Fw:5'-GCCACCCCTAACCCGACCCTAACAAAA-3'Fw:5'-GCCACCCCTAACCCGACCCTAACAAAA-3'Fw:5'-GCCACCCCCTAACCCAACAAAAA-3'Fw:5'-GCCACCCCCTAACCCAACAAAA-3'Fw:5'-CCTTTGCTAGCCCGACCTAACAAAA-3' <t< td=""><td>WFS1</td><td>Fw: 5'-GGAAGCTCAACCCCAAGAA-3'</td></t<>	WFS1	Fw: 5'-GGAAGCTCAACCCCAAGAA-3'
HTR3AFw:5'-GACATCTACAACTTCCCCTTCG-3'Rv:5'-CGGATTCACCTTTCCGCC-3'Rv:5'-CCGACTCTTTTCGGC-3'BTG1Fw:5'-CCAACCAAGCGAGGATATAG-3'RV:5'-TCATCTCCAAGGTACGACCC-3'KIF2BFw:5'-TGGTATGGTGCATGAGTCC-3'ZFP3Fw:5'-CCGTCTGCACGGAGCCTTACGAG-3'Rv:5'-CCCTCCCACTAGGCTGGTG-3'STG1Fw:5'-GGGGTACCGGAGCCCCAACAAATCAG-3'RV:5'-CCGTCGCACTGACTGCCATCTACGAG-3'RV:5'-CCCTCCCACTAGGCTGGTG-3'STP3Fw:5'-GGGGTACCGGAGCCCCAAATCAG-3'RV:5'-GGGGTACCGGAGCCCCAAATCAG-3'RV:5'-GGGGGTACCGGAGCCCCAAATCAG-3'RV:5'-GGGGGTACCGGAGCTCCTGCTCTCTCTCTGCATCT-3'RV:5'-GGGGGTACCCGGAGCTCCAAGAATCAG-3'RV:5'-GGGGGTACCCGGAGCTCCAAGAATCAG-3'RV:5'-GGGGGTACCCGGAGCTCCTAAGGCC-3'RV:5'-GCCACCCCTAAGCCGATCCTAAAGA-3'RV:5'-GCCACCCCTAAGCCGATCCTAAAGA-3'RV:5'-GCCACCCCTAAGCCGATCCTAAAGA-3'RV:5'-CCTTTTTTAGGATCCGGGTTACCGAGCC-3'RV:5'-CCTTTTTAGGATCGGCTTAGGGTGGCC-3'RV:5'-CCTTTCTTAGGGTCGGGTTACCGAGCCCTAACAAAG-3'RV:5'-CCTTTCTTAGGGTCGGGTTACCGAGCCCTAACAAAG-3'RV:5'-CCTTTCTTAGGGCTCGGGTTACCGAGCCCTAACAAAG-3'RV:5'-CCTTTGTTAGGCTCGGGTTACCGAGCCCTAACAAAG-3'RV:5'-CCTTGTTAGGCTTAGCCGAGCCCCTAACAAAG-3'RV:5'-CCTTGTTAGGCTTAGCCGAGCCCTAACAAAG-3'RV:5'-CCTTGTTAGGCTTAGCCGGGTTACCGGGTACCGGGTGACC-3'RV:5'-CTTTGTTAGGCTTAGCCGGGTTACCGGGTACCGACCTAACAAAG-3'R		Rv: 5'-TCTCCACAAAGTCATCCAGC-3'
Rv: 5'-CGGATTTCACCTTTTCGGC-3' FW: 5'-AGCCATTCTTTCGTCCCAG-3' Rv: 5'-CCAACCACAGGGAGATATAG-3' BTG1 FW: 5'-TCGGATATCCCACAGTTTCTCCGC-3' Rv: 5'-TGGGAATACAACGGTAACCC-3' KIF2B FW: 5'-TGGTTATGGTGCATCAGAGTCC-3' ZFP3 FV: 5'-CGTCGACGCCCCACACAAATCAG-3' Rv: 5'-CCCTCCACTAGGCTGGTG-3' FV: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' Rv: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' Rv: 5'-GGGGTACCGGAGCTCCTCTCTCGCCATCT-3' FV: 5'-GGGGTACCGGAGCTCCTCTCTCTCGCACTC-3' RV: 5'-GGGGTACCGGAGCTCCTGAGCGC-3' RV: 5'-GGGGTACCGGAGCTCCTACACAAATCAG-3' RV: 5'-GGGGTACCGGAGCTCCTCTCTCTCTCGCACTC-3' RV: 5'-GGGGGTACCGGAGCTCCTACACAAATCAG-3' RV: 5'-GGGGGTACCGGAAGTTTGTAGATCCACGGC-3' RV: 5'-GGGGACCCGAAGTTGTAGATCCACAGA-3' RV: 5'-GCCACCCCTAAGCGCGCC-3' RV: 5'-GCCCCCCTAAGCCGATCTTAGCGGTGGC-3' RV: 5'-CCTTTTAGGATCGGCTTAGCGGCTGGC-3' RV: 5'-CCTTTTTAGGATCGGCTTAGCGGCTGGC-3' RV: 5'-CCTTTTTAGGATCGGCTTAGCGAGCC-3' RV: 5'-CCTTTTTAGGATCGGCTTAGCGAGCC-3' RV: 5'-CCTTTGCTAACCCGAGCCTAACAAAG-3' RV: 5'-CCTTTGCTAACCCGAGCCTAACAAAG-3' RV: 5'-CCTTTGCTAACCCGAGCCTAACAAAG-3' RV: 5'-CCTTTGCTAACCCGAGCCTAACAAAG-3'	HTR3A	Fw: 5'-GACATCTACAACTTCCCCTTCG-3'
CD47Fw: 5'-AGCCATTCTTTTCGTCCCAG-3' Rv: 5'-CCAACCACAGCGAGGATATAG-3' Rv: 5'-CCAACCTCCCAAGGTAACCC-3' Rv: 5'-TGGGATACCAACGGTAACCC-3' Rv: 5'-TGGTTATGGTGCATGAGTCC-3' Rv: 5'-TGGTTATGGTGCATGAGTCC-3' Rv: 5'-CGTTGGAGGCTTGTCATC-3' Rv: 5'-CCTCCACTAGGCTGGTG-3' <i>ZFP3</i> Fw: 5'-GGGTACCGGAGCCCCAACAATCAG-3' Rv: 5'-CCCTCCACTAGGCTGGTG-3'For cloning Zmynd8 (mouse promoter) <i>ZMYND8</i> (human promoter)Fw: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' Rv: 5'-GGGGGTACCGGAAGCTCGGCTCCTAGTCCACGAG-3' Rv: 5'-GGGGGACCCGAACCAAATCCAGGC-3' Rv: 5'-GGGGGACCCGGAGCTCCTAGTTCTCACAGAA-3' Rv: 5'-GCGACCCCTAAGCCGATCCTAAAAGA-3' Rv: 5'-GCCACCCCTAAGCCGATCCTAAAAGA-3' Rv: 5'-GCCACCCCTAAGCCGATCCTAAAAGA-3' Rv: 5'-GCCTTGTTAGGCTCAGGCTAACGAGC-3' Rv: 5'-CTTTTTAGGATCCGGCTAACCAAAAC-3' Rv: 5'-CTTTGTTAGGCTCGGGTGCC-3' Rv: 5'-CTTTGTTAGGCTCGGGTTAGCAAAGA-3'		Rv: 5'-CGGATTTCACCTTTTCTGGC-3'
Rv: 5'-CCAACCACGGGGGATATAG-3' $BTG1 Fw: 5'-TCATCTCCAAGTTTCTCCGC-3'$ $Rv: 5'-TCGGTATACGGTAACCC-3'$ $Rv: 5'-TGGTTATGGTCCATGAGTCC-3'$ $Rv: 5'-TCGTTGGAGGCCTTGTCATC-3'$ $FW: 5'-GATCTGACTGCCATCTACGAG-3'$ $Rv: 5'-CCCTCCACTAGGCTGGTG-3'$ $For cloning For cloning Fw: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3'$ $Rv: 5'-GGGGTACCGGAGCCCCAACAATCAG-3'$ $Rv: 5'-GGGGGTACCGGAGCTCTCTCTCTCTCTCTCCTCTCTCCACGAG-3'$ $Rv: 5'-GGGGGTACCGGAAGTTTGTAGATCCAGGC-3'$ $Rv: 5'-GGGGGAGCTCGGCTCCTAGTTCTCACAGAA-3'$ $Rv: 5'-GCGACCCCTAAGCCGATCCTAAAAGA-3'$ $Rv: 5'-GCCACCCCTAAGCCGATCCTAAAAGA-3'$ $Rv: 5'-GCCTCTGCTAACCGGCTCGGCTCCTAGGCTGCG-3'$ $Rv: 5'-GCCTCTGCTAACCGAAGCA-3'$ $Rv: 5'-CCTTGCTAACCCGAGCCTAACAAGA-3'$ $Rv: 5'-CCTTGCTAACCCGAGCCTAACAAGA-3'$ $Rv: 5'-CCTTGCTAACCCGAGCCTAACAAGA-3'$ $Rv: 5'-CCTTGCTAACCCGAGCCTAACAAGA-3'$ $Rv: 5'-CCTTGCTAACCCGAGCCTAACAAG-3'$ $Rv: 5'-CCTTGCTAACCCGAGCCTAACAAG-3'$ $Rv: 5'-CCTTGCTAACCCGAGCCTAACAAG-3'$ $Rv: 5'-CCTTGCTAACCCGAGCCTAACAAGA-3'$	CD47	Fw: 5'-AGCCATTCTTTCGTCCCAG-3'
BIGI Fw: 5'-TCATCTCCCACTTTCTCCCC-3' Rv: 5'-TCGCAATACAACGGTAACCC-3' Rv: 5'-TGGTTATGGTGCATGAGTCC-3' <i>KIF2B</i> Fw: 5'-TCGTTGGAGGCTTTGTCATC-3' ZFP3 Fw: 5'-CCTTCGACTGCCATCTACGAG-3' For cloning Zmynd8 (mouse promoter) Fw: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' ZMYND8 (human promoter) Fw: 5'-GGGGGTACCGGAGCTCCTCTCTCTCTCTCTCTCTCTCCTCTCTCCTCCTCCACAGAA-3' Zmynd8 (mouse promoter with RARE mut) Fw: 5'-GCCACCCCTAAGCCGATCCTAAAAGA-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCCACCCCTAAGCCGATCCTAAGGCGC-3' Rv: 5'-CCTTGTCTCTCTCTCTCTCTCACGAGC-3' Rv: 5'-GCCACCCCTAAGCCGATCCTAAAGA-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCCACCCCTAAGCCGATCCTAAGCCAAG-3' Rv: 5'-CTTGTTAGGCTCAGGCTTAGGCTAACAAAG-3' Rv: 5'-CTTGTTAGGCTCAGGCTAACAAGC-3'	DUIC1	Rv: 5'-CCAACCACCAGCGAGGATATAG-3'
KIF2B Fw: 5'-TGCGAATACAGCGTACCC-3' ZFP3 Fw: 5'-TCGTTGGAGGCTTGTCATC-3' For cloning Fw: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' Zmynd8 (mouse promoter) Fw: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' ZMYND8 (human promoter) Fw: 5'-GGGGGTACCGGAGCTCGGCTCTACGAGA-3' Zmynd8 (mouse promoter) Fw: 5'-GGGGGTACCGGAAGTTTGTAGATCCAGGC-3' ZMYND8 (human promoter) Fw: 5'-GGGGGTACCGGAAGTTCTCACAGAA-3' Zmynd8 (mouse promoter with RARE mut) Fw: 5'-GCCACCCCTAAGCCGATCCTAAAAGA-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCTATCGCTAAGCCGATCCTAAGCGAGCC-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCTATGCTAACCGAGCCTAACAAAG-3' Rv: 5'-CTTTGTTAGGATCCGGGCTCAGGCTGCGC-3' Rv: 5'-CTTTGTTAGGATCGGAGCCTAACAAAG-3'	BIGI	Fw: 5'-TCATCTCCAAGTTTCTCCGC-3'
RV: 5'-IGGTIAGGIGCATGAGICC-3' ZFP3 Rv: 5'-CCTTGGAGGCTGGTGG-3' For cloning Rv: 5'-CCCTCCACTAGGCGAGCCCAACAAATCAG-3' Zmynd8 (mouse promoter) Fw: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' ZMYND8 (human promoter) Fw: 5'-GGGGGTACCGGAGCTCGGCTCCTACGAGC-3' Zmynd8 (mouse promoter with RARE mut) Fw: 5'-GGCACCCCTAAGCCGATCCTAAGAA-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCCACCCCTAAGCCGATCCTAAGAA-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCCACCCCTAAGCCGAGCCTAACAAAGA-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCCTCTTGCTAACCCGAGCCTAACAAAGA-3'	VIEOP	RV: 5 - TGCGAATACAACGGTAACCU-3
ZFP3 Fw: 5'-GATCTGACTGCACCACAGA-3' Rv: 5'-CCTTCGACTGCCATCTACGAG-3' Rv: 5'-CCTTCCACTAGGCTGGTG-3' For cloning Fw: 5'-GGGGGTACCGGAGCCCCAACAAATCAG-3' Zmynd8 (mouse promoter) Fw: 5'-GGGAGCTTCTCTCTCTCTCTCTCTCGATCT-3' ZMYND8 (human promoter) Fw: 5'-GGGGGGTACCGGAAGTTTGTAGATCCAGGC-3' Zmynd8 (mouse promoter with RARE mut) Fw: 5'-GGCACCCTAAGCCGATCCTAAAAGA-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCTTTGTCTCAACAAAGA-3' Rv: 5'-GCTTTGCTAACCCGAGCCTAAGGGGTGGCG-3' Rv: 5'-CCTTTGTAAGCCCGAGCCTAACAAAG-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCTTTGCTAACCCGAGCCTAACAAAG-3'	KII 2D	P_{W} : $S = 1GGTTATGGTGCATGAGTCC=S$ P_{W} : $S' = PCCPTPCCACCCPTPTCPCATCC=S'$
Image: Structure Rv: 5'-CCCTCCACTAGGCTGGTG-3' Rv: 5'-CCCTCCACTAGGCTGGTG-3' Rv: 5'-CCCTCCACTAGGCTGGTG-3' Rv: 5'-CGGGGTACCGGAGCCCCAACAAATCAG-3' Rv: 5'-GGAAGCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	7FP3	F_{W} . 5'-CATCTCACTACCATCTACCAC-3'
For cloning Fw: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' Zmynd8 (mouse promoter) Rv: 5'-GGAAGCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	2110	Rv: 5'-CCCTCCACTAGGCTGGTG-3'
For coming Fw: 5'-GGGGTACCGGAGCCCCAACAAATCAG-3' Zmynd8 (mouse promoter) Fw: 5'-GGAAGCTTCTCTCTCTCTCTCTCTCGCATCT-3' ZMYND8 (human promoter) Fw: 5'-GGGGGAGCCCCAACAAATCAG-3' Zmynd8 (mouse promoter with RARE mut) Fw: 5'-GCGACCCCTAAGCTCGGCTCCTAGAAAGA-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCCTTTTTAGGATCCGGCTTAGCGGGTGGC-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCTTTGTCAACCGAGCCTAACAAAG-3' Rv: 5'-CTTTTGTAGGCCCGAGCCTAACAAAG-3' Rv: 5'-CTTTGTCAACCGAGCCTAACAAAG-3'	F	
Zmynds (nouse pronoter) Fw: 5 - GGGGTACCGGAGCCCCAACAAATCAG-S Rv: 5 '-GGGAGCTCTCTCTCTCTCTCTCTCTCGCATCT-3' ZMYNDs (human promoter) Fw: 5'-GGGGGAGCTCGGAGCTCTAGATCCAGGC-3' Zmynds (mouse promoter with RARE mut) Fw: 5'-GCCACCCCTAAGCCGATCCTAAAGA-3' ZMYNDs (human promoter with RARE mut) Fw: 5'-GCTTTTGGGATCCGGCTTAGCGGCTGGGGGGCG-3' ZMYNDs (human promoter with RARE mut) Fw: 5'-CTTTTGGTAAGCCGGGCTCAGAGAG-3' Rv: 5'-CTTTGTTAGGATCCGGCTTAGCAAAGAGC-3'	For cloning Zwww.d ^g (mouse promotor)	
ZMYND8 (human promoter) Fw: 5'-GGGGAGCTCGGCTACGAGCC-3' Zmynd8 (mouse promoter with RARE mut) Fw: 5'-GCCACCCCTAAGCCGATCCTAAAGA-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCTCTTAGGATCCGAGCCTAAGGGTGGC-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCTCTTGCTAAGCCGAGCCTAAGCAGAG-3' Rv: 5'-CTTTTGTTAGGATCGGCCTAACAAAG-3' Rv: 5'-CTTTGTTAGGATCGGCCTAACAAAG-3' Rv: 5'-CTTTGTTAGGATCGGCCTAACAAAG-3'	Zmynuo (mouse promoter)	FW: 5 - GGGGTAUUGGAGUUUUAAUAATUAG-5 Rv: 5'-CCAACCTTOTOTOTOTOTOTOTOTOTOTOTOTOTOT-2'
Zmynd8 (mouse promoter with RARE mut) Fw: 5'-GGGGAGCTCGGCTCTAGGCCGAGA-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCTCTTGCTAACCCGAGCCTAACCAAAG-3' Rv: 5'-CTTTTGTTAGGATCCGGGCTAACAAAG-3' Rv: 5'-CTTTGTTAGGATCCGAGCCTAACAAAG-3'	ZMYND8 (human promoter)	F_W . 5'-CCCCCTACCCCAACTTTCTACATCCACCC-3'
Zmynd8 (mouse promoter with RARE mut) Fw: 5'-GCCACCCCTAAGCCGATCCTAAAGA-3' Rv: 5'-TCTTTTAGGATCGGCTTAGGGGTGGC-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-CTTTGTTAGGCTCGGGCTAACAAAG-3' Rv: 5'-CTTTGTTAGGCTCGGGCTAACAAAG-3' Rv: 5'-CTTTGTTAGGCTCGGGCTAACAAAG-3'	Zanine (numan promoter)	Rv: 5'-GGGGAGCTCGGCTCCTAGTTCTCACAGAA-3'
Rv: 5'-TCTTTTAGGATCGGCTTAGGGGTGGC-3' ZMYND8 (human promoter with RARE mut) Fw: 5'-GCTCTTGCTAACCCGAGCCTAACAAAG-3' Rv: 5'-CTTTGTTAGGCTCGGGTTAGCAACAAG-3'	Zmynd8 (mouse promoter with RARE mut)	Fw: 5'-GCCACCCCTAAGCCGATCCTAAAAGA-3'
ZMYND8 (human promoter with RARE mut) Fw: 5'-GCTCTTGCTAACCCGAGCCTAACAAAG-3' Rv: 5'-CTTTGTTAGGCTCGGGTTAGCAAGAGC-3'	······································	Rv: 5'-TCTTTTAGGATCGGCTTAGGGGTGGC-3'
Rv: 5'-CTTTGTTAGGCTCGGGTTAGCAAGAGC-3'	ZMYND8 (human promoter with RARE mut)	Fw: 5'-GCTCTTGCTAACCCGAGCCTAACAAAG-3'
		Rv: 5'-CTTTGTTAGGCTCGGGTTAGCAAGAGC-3'

had a tight association to chromatin by fractionation experiment, where even 0.5% Nonidet P-40 treatment could not release the protein to the non-chromatin fraction in HEK293 cells (Fig. 1*A*). Histone H3 and tubulin were used as nuclear and cytosolic markers, respectively (Fig. 1*A*). Next, we investigated the ability of ZMYND8 to interact with core histones in HEK293 cells. By co-IP with anti-ZMYND8 antibody, we observed a strong interaction with histone H3 and H4 (Fig. 1*B*) but not with histone H2A and H2B. However, the ability of ZMYND8 to interact with core histones could also be an indirect effect of preferential binding of ZMYND8 to other chromatin protein(s). To elucidate that, we performed an *in vitro* interaction of the PBP module of ZMYND8 with recombinant histones and core histones. Although ZMYND8 did not interact with individual histone H3 and H4 (Fig. 1*C, panel I* and *panel II*), it showed a strong interaction with histone H3 and H4 of core histone (Fig. 1*D*). These results indicate that the interaction with core histones is direct, although there is a requirement of a histone post-translational modification. Similar interaction of the PBP module of ZMYND8 with purified chromatosome from HeLa cells also showed its association to histone H3 and H4 (Fig. 1*E*). These results clearly indicate that ZMYND8 is a core histone H3/H4-interacting protein having a tight association with chromatin.

ZMYND8 Interacts with Modified Histone H3.1 and H4 through Its Comprehensive Chromatin-binding Module in Vitro—The N terminus of ZMYND8 includes the chromatininteracting domains, viz. PHD, bromodomain, and PWWP motif (PBP module in combination), followed by the MYND finger at the C terminus (Fig. 2A). We speculated that the his-



FIGURE 1. **Human transcription factor ZMYND8 is a chromatin-associated protein.** *A*, chromatin fractionation experiment with increased detergent concentration (0.1%-0.5%) in HEK293 cells was performed. ZMYND8 is associated with chromatin (*C*) fraction even upon 0.5% Nonidet P-40 treatment. Histone H3 and tubulin were used as markers for chromatin (*C*) and non-chromatin (*NC*) fractions. *B*, co-IP with α -ZMYND8 antibody from HEK293 cells followed by immunoblotting with α -H3, α -H4, α -H2B, and α -H2A antibodies. IgG pull down served as a negative control. *IP*, immunoprecipitation; *WCE*, whole cell extract. *C*, GST-PBP (of ZMYND8) or GST protein interaction with recombinant histone H3 (*panel I*) and H4 (*panel I*) and α -H4 (*panel II*) antibodies. *D*, core histone (from chicken erythrocytes) interaction with GST-PBP or GST proteins. GST pulldown assay followed by Western blot analysis with α -H3, α -H4 α -H2B, and α -H2A antibodies was performed. *E*, interaction of chromatosome (from HeLa cells) with GST-PBP or GST proteins. GST pull down was performed followed by and immunoblotting with α -H3 and α -H4 antibodies.

tone interaction ability of ZMYND8 is through its PBP module. For that we expressed and purified GST-PBP chromatin-binding modules of ZMYND8. We also purified GST-tagged PWWP, PHD, and bromodomain individually. To characterize the modified histone-binding ability of ZMYND8, MODified Histone Peptide Array (CelluSpots array) analysis was performed with purified PBP protein. H3K36Me2 (spot 3), H3K36Me3 (spot 4), and H4K16Ac (spot 6) were the most prominent interactors (Fig. 2B, panel I). H3K18Ac in combination with H3K14Ac (spot 7) or with R17Me2s/2a (spot 8/9/10) also showed positive interaction, which can be attributed to the high sequence homology between the H3K36- and H3K14/18encompassing sequence (Fig. 2B, panel II). Furthermore, peptide pulldown assays were performed to validate the interaction biochemically. H3.1K36Me2 and H3.1K36Me3 showed a better interaction in comparison with H3.1K36Me1 peptide (Fig. 2C,

panel I, compare lanes 3-5) with PBP module. The PHD finger and PWWP motifs are also well characterized methyl binders (24–26). Similar experiments were done with isolated PWWP motif or PHD finger and histone peptides H3.1K36Me1, H3.1K36Me2, and H3.1K36Me3. Neither of the domains in isolation could bind to methylated histone H3.1K36 peptides (Fig. 2C, panels II and III, compare lanes 3-5). Remarkably, GST-PBP showed no preferential interaction for methylated histones on H3.3 backbone (Fig. 2C, panel IV). We also investigated its ability to interact with other H3.1- or H4-methylated peptides (Fig. 2C, panel V) and found no other significant interactions. This clearly indicates that integrated PBP module is critical for recognition of H3.1K36Me2/Me3 only. We subsequently investigated the binding ability of the PBP module for acetylated histones and found that H4K16Ac has a better preference compared with any of the other site-specific acetylated histone H4





FIGURE 2. ZMYND8 interacts preferentially with histone H3.1K36Me2/Me3 and H4K16Ac through its putative chromatin-binding module in vitro. A, schematic domain organization of ZMYND8. B, interaction of GST-PBP module of ZMYND8 with MODified Histone Peptide Array (CelluSpots array). Preferential histone peptide interactors of GST-PBP were scored by probing the array with α -GST antibody. GST-PBP showed significant interaction with H3K36Me2 (spot 3), H3K36Me3 (spot 4), and H4K16Ac (spot 6). H3K14Ac K18Ac alone or in combination with R17Me2a/s or H3K18Ac R17Me2a also showed positive interaction (spots 7-10) (panel I). Sequence alignment of the canonical H3(10-18), H3(31-40) by ClustalW. The conserved amino acids are marked in red (panel II). C, interaction of GST-PBP (panel I), GST-PWWP (panel II), and GST-PHD (panel III) with biotinylated mono/di/tri-methylated H3.1K36. Similar interactions of GST-PBP were with H3.3K36-methylated peptides (panel IV). GST-PBP interaction were with biotinylated mono/di/tri-methylated H3K27 and H4K20 peptides (panel V). D, interaction of GST-PBP (panel I), GST-bromo (panel II), with biotinylated H4-K5/K8/K12/K16/K20 acetylated peptides. Interaction of GST-PBP (panel /II) and GST-bromo (panel IV) module with other acetylated histone H3 peptides (H3K9Ac, H3K14Ac, and H3K27Ac). E, unmodified H4(11–25) and H3(22–44) (panel I, lanes 3 and 4) showed minimal interaction as compared with H4K16Ac and H3.1K36Me2 peptides (panel I, lanes 5 and 6) with GST-PBP. Furthermore, GST-PBP showed preferential interaction with H3.1K36Me2 compared with H3.3K36Me2 (panel II, compare lanes 3 and 5). F, binding isotherms for the interaction of His-PBP (of ZMYND8) with indicated histone peptides as obtained from steady state fluorescence spectroscopy. Data points for H3K36Me3 H3K36Me2 and H3K36Me1 are indicated by circle (red), square (black), and triangle (blue), respectively (panel I). Binding isotherm for the interaction of His-PBP and H4K16Ac (FAM-conjugated) peptide as obtained from steady state fluorescence spectroscopy (panel II). G, sequence alignment of ZMYND8 and ZMYND11 showing conserved critical residues in Bromo-PWWP (*BP*) module by using ESPript. *H*, molecular modeling of ZMYND8 with ZMYND11 BP module was done by using Modeler version 9.13. Modeled bromodomain (*I*) and PWWP domain (*J*) structure highlighting the predicted critical residues involved in interaction with acetylated H4K16 and methylated H3.1K36, respectively. K and L, comparative binding ability of GST-PBP wild type (WT) or Y227A/N228A mutant (K) or F307A mutant (L) with H4K16Ac and H3.1K36Me2 peptides (panels I and II).



TABLE 3

The K_d values of fluorescence data are presented below

Apparent dissociation constant was obtained from steady state fluorescence spectroscopy. At 25 °C, the K_d values were averaged over three separate experiments, with error calculated as the standard deviation between runs.

Peptide	K _d
	μм
H3.1K36Me3	0.45 ± 0.03
H3.1K36Me2	0.23 ± 0.07
H3.1K36Me1	19.7 ± 2.24
H3.1K36 unmodified	Undetermined
H4K16Ac	0.75 ± 0.1
H4K16 unmodified	Undetermined

(at Lys-5, Lys-8, Lys-12, and Lys-20) peptides (Fig. 2D, panel I, compare lanes 3-7). However, histone H3 peptides acetylated at Lys-9, Lys-14, or Lys-27 did not show any interaction with ZMYND8 (Fig. 2D, panel III, lanes 3-5). Similar experiments done with isolated bromodomain, the acetylation binding module, also showed a good interaction with H4K16Ac but not with other acetylated H4 (Fig. 2D, panel II, compare lanes 3-7) or acetylated histone H3 (Fig. 2D, panel IV, compare lanes 3-5) peptides. We observed minimal binding of unmodified histone peptides, H3 (22-44 residues) and H4 (11-25 residues) to the PBP module of ZMYND8 confirming its preference for sitespecifically modified histones at H3.1K36Me2/Me3 and H4K16Ac (Fig. 2E, panel I, compare lanes 3-6). Similarly, no significant interaction was observed for H3.3 (22–44 residues) or H3.3K36Me2 peptides with PBP module indicating preferential interaction with H3.1K36Me2/Me3 peptides (Fig. 2E, panel II, compare lanes 3-6).

The selective interaction of ZMYND8 with H3.1K36-methylated and H4K16-acetylated peptides was further quantified by fluorescence spectroscopy. The PBP module was titrated with H3.1K36Me0/Me1/Me2/Me3 peptides, and quenching of the fluorescence intensity of the tryptophan residue at the peptide binding pocket of the protein was measured. No appreciable binding was seen with H3.1K36Me0 peptide. H3.1K36Me2 peptide ($K_d \sim 0.23 \,\mu$ M) showed 2-fold higher affinity compared with H3.1K36Me3 ($K_d \sim 0.45 \,\mu$ M) (Fig. 2*F*, panel I, and Table 3). In comparison, binding affinity of H3.1K36Me1 ($K_d \sim$ 19.7 μ M) was 85-fold weaker compared with H3.1K36Me2 peptide (Fig. 2F, panel I, and Table 3). Because the bromodomain, which is crucial for the interaction with H4K16Ac peptide, is devoid of tryptophan residues, we performed extrinsic fluorophore conjugation to H4 or H4K16Ac peptides with FAM. Subsequently, the FAM-conjugated peptides were titrated with the PBP module in increasing concentrations to score the interaction. Although no appreciable binding was seen for histone H4 peptide with the PBP module, H4K16Ac peptide showed significant interaction ($K_d \sim 0.75 \ \mu$ M) (Fig. 2F, panel II, and Table 3). Thus, the specificity in the interaction of ZMYND8 with modified histone H3.1K36Me2/H4K16Ac was reconfirmed.

As ZMYND8 shows similar domain organization (Bromo-PWWP) as well as the amino acid sequence identity to ZMYND11 (33% for the Bromo-PWWP module) (Fig. 2*G*), Bromo-PWWP domain of ZMYND8 was modeled with reference to ZMYND11 structure (Fig. 2*H*). The modeled bromodomain structure consists of a four-helix bundle interspersed by ZA and BC loops, which is a conserved canonical structural

ZMYND8, Regulates ATRA-responsive Genes

feature (Fig. 21). The asparagine residue (Asn-228), which is involved in the acetylated lysine recognition, has also been highlighted in stick representation (Fig. 21). The PWWP domain adopts a five-bladed β -barrel fold with an α -helix at the C terminus (Fig. 2J). The H3.1K36Me2-binding aromatic residues (Phe-288, Trp-291, Phe-307, and Asp-312) are in stick representation in the PWWP structure (Fig. 2J). We mutated the active site residues of the bromodomain (i.e. Tyr-227 and Asn-228) and the aromatic cage of PWWP (Phe-307) to alanine. The Y227A/N228A double mutation in PBP module of ZMYND8 showed compromised binding to H4K16Ac peptide (Fig. 2K, panel I, compare lanes 5 and 6). Similarly, PWWP F307A mutation in the PBP module showed minimal interaction to H3.1K36Me2 (Fig. 2L, panel I, compare lanes 5 and 6). Y227A/N228A double mutant, however, showed no alteration in H3.1K36Me2 binding as compared with the wild type protein (Fig. 2K, panel II, compare lanes 5 and 6). In parallel, wild type and F307A mutant proteins showed significant H4K16Ac binding (Fig. 2L, panel II, compare lanes 5 and 6). This indicates that Tyr-227 and Asn-228 residues are critical for H4K16Ac binding, and the aromatic cage in PWWP is critical for H3.1K36Me2 binding. These results confirm that the bromodomain and the PWWP motif are responsible for interacting with H4K16Ac and H3.1K36Me2 respectively, although the comprehensive organization of PBP, harboring certain critical residues in the modified histone binding pocket, is essential for mediating this interaction.

ZMYND8 Interacts with H3.1K36Me2 and H4K16Ac Histones ex Vivo—We subsequently wanted to score the binding preference of ZMYND8 for canonical or variant histone in an ex vivo context for which FLAG-H3.1- or FLAG-H3.3-transfected HEK293 cells were subjected to M2-agarose pull down and immunoblotted with anti-ZMYND8 antibody. We observed a preferential interaction of histone H3.1 with ZMYND8 and histone H3.3 with ZMYND11 (Fig. 3A, panel I) and subsequently quantified each of these interactions (Fig. 3A). A sequence alignment of ZMYND8 and ZMYND11 (Fig. 3A, panel II) and H3.1 and H3.3 (Fig. 3A, panel III) was performed to understand these binding preferences.

We subsequently performed co-IP assays to understand its modified histone binding preference ex vivo. Endogenous ZMYND8 showed robust interaction with H3K36Me2, compared with H3K36Me3 (Fig. 3B). Here, H4K16Ac was also found to be associated with endogenous ZMYND8 (Fig. 3B). Genome-wide distribution of H3K36Me2 and H4K16Ac epigenetic marks has been previously reported (27-29). The NSD2 (Nuclear receptor SET Domain-containing family of histone lysine methyltransferase) target genes, for example TGFA, MET, and RRAS2, were found to have high H3K36Me2 occupancy (Fig. 3C, panel I). However, several key developmental genes, including HOXA9, WNT1, and TP53, showed a high abundance of H4K16Ac (Fig. 3D, panel I). Interestingly, we observed a significant occupancy of ZMYND8 at these H3K36Me2- and H4K16Ac-enriched gene loci in HEK293 cells (Fig. 3, C, panel II, and D, panel II). In contrast, ZMYND8 had meager binding to the region of the genome with a low abundance of H3K36Me2 and H4K16Ac levels (marked as -ve Control in panels I and II of





FIGURE 3. Preferential interaction of ZMYND8 with H3.1K36Me2/H4K16Ac ex vivo. A, interaction of ZMYND8 with H3.1 or H3.3 histones. HEK293 cells were transiently transfected with FLAG-H3.1/FLAG-H3.3. M2-agarose pull down was done and subsequently probed with α-ZMYND8 antibody. ZMYND11 was used as a control. Western blot quantification showed the preferential interaction of ZMYND8 with H3.1 and ZMYND11 with H3.3 (panel I). Blots were quantified using ImageJ software from National Institutes of Health. Sequence alignment of histone H3 binding pocket of ZMYND11 and similar sequence stretch in ZMYND8 by ClustalW. Critical residues marked in blue mediating H3.3 binding in ZMYND11 (Asn and Ārg) are substituted in ZMYND8 (by Cys and Lys) (panel II). Sequence alignment of histone H3.1 and H3.3 spanned amino acids 20-40. The variation at the N-terminal tail is at amino acid Ala-31 for H3.1 which is replaced by Ser-31 for H3.3 (marked in red) (panel III). B, interaction of ZMYND8 with modified histones. Endogenous ZMYND8 was co-immunoprecipitated from HEK293 cells and immunoblotted for ZMYND8, H3K36Me2, H3K36Me3, and H4K16Ac. IgG pull down served as a negative control. C, ChIP assays were performed in HEK293 cells with α-H3K36Me2 and α-ZMYND8 antibodies to check for enrichment of H3K36Me2 (panel I) and ZMYND8 (panel II) at RRAS2, TGFA, and MET gene loci and a negative control region (depleted of H3K36Me2 and H4K16Ac). Two separate regions of each of the genes (5 and 24 kb for RRAS2, 22 and 57 kb for TGFA, and 3 and 26 kb for MET, downstream from start site) were selected for designing primers. D, similarly, ChIP assays were performed in HEK293 cells with α -H4K16Ac and α -ZMYND8 antibodies to show enrichment of H4K16Ac (panel I) and ZMYND8 (panel II) at HOXA9, WNT1, and TP53 gene loci and a negative control region (depleted of H3K36Me2 and H4K16Ac). Two separate regions of 646 and 1890 bp downstream from the start site were selected for designing primers from HOXA9 gene. WNT1 primers were for promoter region, whereas the TP53 primer was designed 11 kb downstream. Quantitative PCR was done, and relative fold was plotted normalizing by IgG. For H3K36Me2 and H4K16Ac, ChIP relative fold was further normalized to endogenous H3 and H4, respectively. At least three separate experiments were performed. Error bars show standard deviation.

Fig. 3, *C* and *D*), implicating that the recruitment of the protein to the genome is through its ability to interact with these modified histones.

Minimal PBP Module of ZMYND8 Is Critical for Its Recruitment to the Modified Histones of Chromatin—We hypothesized that the PBP module of ZMYND8 is the minimal requirement for its chromatin-binding ability. To confirm this, FLAG-conjugated constructs of wild type and PBP-deleted ZMYND8 were transfected into HeLa cells, and immunofluorescence staining with anti-FLAG and anti-H3K36Me2/-H4K16Ac was performed. The extent of co-localization of H3K36Me2 with wild type (Pearson's coefficient 0.78) was more significant than with PBP-deleted (Pearson's coefficient 0.47) (Fig. 4A, compare *panels I* and *II*). Similarly, H4K16Ac and wild type showed better co-localization (Pearson's coefficient 0.68) than with the mutant (Pearson's coefficient 0.29) (Fig. 4A, compare *panels III* and *IV*). Co-IP assays with anti-FLAG antibody also established that unlike wild type, PBP deleted-ZMYND8 showed a poor interaction with H3K36Me2 and H4K16Ac marks (Fig. 4B). However, both wild type and PBP-deleted ZMYND8 showed comparable interaction with HDAC1 and CHD4 (Fig. 4B). To further confirm whether the MYND domain is also involved in mediating the interaction with histones, we expressed and purified the GST-MYND domain of ZMYND8. In a pulldown assay with H4K16Ac and H3.1K36Me2 peptides, specific interaction could be detected with GST-PBP but not GST-MYND (Fig. 4C). Finally, the requirement of the PBP module of the protein for being targeted to its binding sites was assessed. Here, we selected TP53 and RRAS2 (24 kb) as they showed significant enrichment of H4K16Ac and H3K36Me2, respectively (Fig. 4D). The genes harboring H3K36Me2 and H4K16Ac had high occupancy of wild type but not the PBP-deleted construct as seen by ChIP assays (Fig. 4D). These results clearly indicate that the minimum PBP module of ZMYND8 is critical for its recruitment to chromatin through its modified histone interacting partners.



FIGURE 4. **Chromatin binding module of ZMYND8** is essential for its histone interaction. *A*, HeLa cells were transiently transfected with FLAG-WT ZMYND8 or FLAG- Δ PBP ZMYND8, co-stained with α -FLAG and either α -H3K36Me2 or α -H4K16Ac antibodies. The Pearson's coefficient for FLAG-WT ZMYND8 and H3K36Me₂/H4K16Ac was >0.5, whereas that for FLAG- Δ PBP ZMYND8 and H3K36Me₂/H4K16Ac was <0.5. *B*, HEK293 cells were transiently transfected with FLAG-WT or FLAG- Δ PBP ZMYND8, and whole cell extracts were subjected to M2-agarose FLAG pull down and immunoblotted with α -FLAG, α -H3K36Me2, α -H4K16Ac, α -HDAC1, and α -CHD4 antibodies. *C*, interaction of GST-PBP or GST-MYND with biotinylated H4K16Ac and H3.1K36Me2 peptides. Western blot analysis was done with α -GST antibody. *D*, ChIP assay was performed after transiently transfecting FLAG- Δ PBP ZMYND8 in HEK293 cells with α -FLAG antibody. Relative fold enrichment at *TP53* (11 kb) and *RRAS2* (24 kb) gene loci was scored by quantitative PCR normalized to IgG. At least three separate experiments were performed. *Error bars* show standard deviation.

ZMYND8 Is Itself an ATRA-responsive Gene and Regulates Other RA-inducible Genes—To understand the role of ZMYND8 in regulating transcription in chromatin context, we used ATRA, which is a well studied transcription inducer (11). At first, we attempted to check whether there was an alteration in expression of ZMYND8 upon ATRA treatment. For this, we selected SH-SY5Y cells that showed elevated expression of *TAU, TUJ1, NAV1.2,* and *SNAP25* (30–32) and down-regulation of *REST,* a pluripotency marker leading to neurite formation (33) in response to RA. A similar alteration of gene expression upon RA stimulation was observed (Fig. 5*A*). *ZMYND8* gene showed a progressive hyper-expression after 2 or 4 days of ATRA treatment (Fig. 5*A*). Similarly, ZMYND8 increased in protein abundance with progressive days of RA treatment (Fig. 5*B*) where TAU was used as a positive control.

The increase in ZMYND8 in both RNA and protein levels led us to perform its promoter analysis. We observed the presence of RARE sequence at the upstream region of *ZMYND8* in both human and mouse genome and subsequently cloned them in pGL3-basic vector to check their promoter activity. Indeed, we



found an ATRA-induced firing of the luciferase fusion gene constructs in both mouse (Neuro2A) and human (SH-SY5Y) cells (Fig. 5*C*, *panels III* and *IV*). Mutating the RARE sequence led to a significant reduction in *ZMYND8* promoter activity in both the cells (Fig. 5*C*, *panels III* and *IV*). These results clearly indicate that *ZMYND8* is itself an ATRA-responsive gene.

Next, we looked for the occupancy of ZMYND8 on the different ATRA-responsive genes, including *TUJ1*, *TAU*, *DRD2*, *NAV1.2* and *SNAP25* (34) by ChIP assays (Fig. 5, *D* and *E*). We have selected primers for two different regions of the gene, promoter (harboring the RARE element), and gene body. Upon ATRA treatment, the occupancy of ZMYND8 at the promoter as well as gene body of *TUJ1*, *TAU*, *DRD2*, *NAV1.2*, and *SNAP25* showed significant increase (Fig. 5, *D* and *E*). The enrichment of ZMYND8 at the promoter and gene body of the ATRA-responsive genes could be through its ability to interact with transcription machinery components or modified histones. We at first investigated the cause of selective enrichment of ZMYND8 at the gene body. H3K36Me2 and H4K16Ac have been shown to be significantly enriched at the gene body by ChIP-Seq studies in different cell lines (27–29). To understand whether the preferential recruitment of ZMYND8 to the gene body of the ATRA-inducible genes in SH-SY5Y cells is through its modified histone-binding ability, we analyzed the histone PTM on these genes (Fig. 5, *F* and *G*). We observed an increased occupancy of H3K36Me2 and H4K16Ac by RA in SH-SY5Y cells in *TUJ1, TAU, DRD2, NAV1.2* and *SNAP25* (Fig. 5, *F* and *G*). The reason of recruit-



ment of ZMYND8 at the promoter elements of these genes has been investigated later.

In addition, we monitored the altered level of different epigenetic marks in ATRA-treated SH-SY5Y cells. Among H3K36Me1, H3K36Me2, and H3K36Me3 signatures, H3K36Me2 mark showed a significant elevated level (Fig. 5*H*). However, RA treatment increased H4K16Ac appreciably, although the H3K9Ac signature did not show significant change (Fig. 5*H*). Thus, ATRA modulates specific histone modifications not only in gene-specific manner but also in a global context.

Our next attempt was to examine the involvement of ZMYND8 in the regulation of these ATRA-responsive genes. We knocked down ZMYND8 in DMSO or RA-treated SH-SY5Y cells. The reduction of ZMYND8 expression upon siRNA transfection was scored by qRT-PCR and Western blotting analysis (Fig. 5, *I* and *J*). Knocking down ZMYND8 compromised the expression of different ATRA-responsive genes, including TUJ1, TAU, DRD2, NAV1.2, and SNAP25 significantly (Fig. 5K). However, the expression of *REST* was marginally increased upon silencing of ZMYND8 (Fig. 5K). The expression of glial markers, including *GFAP* and *VIM* (36, 37), remained almost unaltered following ZMYND8 silencing (Fig. 5K). These results clearly show that ZMYND8 gets recruited to the ATRA-responsive genes and regulates their expression.

ZMYND8 Shows Selective Interaction with RNA Polymerase II Phosphorylated at Ser-5 in a DNA Template-dependent Manner—We have previously shown that upon ATRA treatment, ZMYND8 recruitment at the promoter element (harboring RARE sequence) was significantly high (Fig. 5D). Hence, we hypothesized its possible association with RNA polymerase II transcription machinery. Interestingly, by performing coimmunoprecipitation assays, we found that ZMYND8 interacts with transcription-initiation-competent RNA pol II S5P but not with transcription elongation/termination-competent RNA pol II S2P complex (Fig. 6A, compare lanes 1 and 3). Reciprocal interactions indicated that RNA pol II S5P but not S2P interacted with ZMYND8 (Fig. 6, C and D). Here, interac-

ZMYND8, Regulates ATRA-responsive Genes

tion with RNA pol II non-C-terminal domain was used as control (Fig. 6, A and B). We subsequently wanted to understand whether there is any alteration in its preferential interaction with RNA pol II S5P in presence or absence of ATRA. By immunoprecipitating RNA pol II S5P, the interaction with ZMYND8 did not alter in DMSO- or ATRA-treated SH-SY5Y cells (Fig. 6E). The interaction of ZMYND8 and RNA pol II machinery could be DNA template-dependent or -independent. Because the interaction between the two did not alter the presence or absence of ATRA, we predicted this complex formation onto the DNA template. We set immunoprecipitation with RNA pol II S5P after DNase I digestion of the lysates. In accordance with our speculation, we indeed see a sharp decrease in its association with ZMYND8 upon DNase I digestion of lysates (Fig. 6F). To further confirm the role of ZMYND8 in regulating transcription of ATRA-responsive genes, we performed ChIP assays with RNA pol II S5P following silencing of ZMYND8 gene expression. Indeed, we observed a significant reduction of RNA pol II S5P recruitment to chromatin in the absence of ZMYND8, even after ATRA induction (Fig. 6G). These results clearly indicate that ZMYND8 is a key component of transcription machinery complex having a significant role in mediating transcription initiation.

ZMYND8 Regulates Global Gene Transcription in CHD4-independent Manner—ZMYND8 is a component of the coregulator complex network having an extensive interaction with transcription machinery (5, 38). Recently ZMYND8 has been established to be a component of the NuRD chromatin remodeling complex (39) and can influence gene transcription (5). In an attempt to comprehend whether ZMYND8 can regulate global gene expression only when it remains associated with the NuRD complex, we performed microarray analysis in ZMYND8 knocked down HeLa cells. Overall, 331 genes were up-regulated and 438 genes were down-regulated upon ZMYND8 silencing. The cluster diagram is represented in Fig. 7A. The microarray data has been validated by qRT-PCR analysis where candidate up-regulated (*E2F3, TFEB,* and *BMP8A*)

FIGURE 5. ZMYND8 is ATRA-responsive and regulates other RA-inducible genes. A, ATRA treatment of SH-SY5Y cells for 2 and 4 days, respectively, leads to an increase in ZMYND8 RNA level. TAU, TUJ1, NAV1.2, SNAP25, and REST were used as controls. Relative mRNA level was plotted for ATRA-treated differentiated cells over DMSO-treated undifferentiated cells and normalized to GAPDH. At least three individual experiments were performed. Error bars show standard deviation. B, alteration in the expression of ZMYND8 protein abundance in SH-SY5Y cells upon ATRA treatment for 2 and 4 days. Western blotting was done by probing with α-ZMYND8, α-TAU, and α-GAPDH antibodies. GAPDH was used as loading control. At least three individual experiments were performed. Error bars show standard deviation. Blots were quantified using ImageJ software from National Institutes of Health. C, schematic diagram shows the upstream regulatory region of mouse (panel I) and human (panel II) ZMYND8 genes with the arbitrary position of RARE and the primer pairs used to clone those regions into pGL3-basic vector. The respective reporter constructs were transiently transfected into Neuro2A (panel III) and SH-SY5Y (panel IV) cells, respectively, with/without ATRA treatment followed by luciferase assay. The activities are shown as mean fold enhancement compared with the empty vector after normalization with Renilla luciferase activity. Here, the constructs containing mutated RARE sequence are named as RARE-mut. Each transfection was performed in triplicate, and the experiments were repeated at least three times. Error bar shows standard deviation. D-G, relative enrichment of ZMYND8 on the RARE harboring sequence of promoter of RA-responsive genes (*TUJ1*, *TAU*, *DRD2*, *NAV1.2*, and *SNAP25*) was observed (*D*). Similar enrichment of ZMYND8 (*E*), H3K36Me2 (*F*), and H4K16Ac (*G*) onto gene body region of *TUJ1*, *TAU*, *DRD2*, *NAV1.2*, and *SNAP25* genes was monitored. ChIP assays were performed after 4 days of ATRA treatment in SH-SY5Y cells with α -ZMYND8 antibody. Relative fold was calculated by normalizing ZMYND8 with IgG for both DMSO (control) and ATRA-treated cells. At least three separate experiments were performed. Error bars show standard deviation. H, alteration in the expression of different epigenetic marks upon ATRA treatment for 2 and 4 days. Western blotting was done by probing with α-H3K36Me1, α-H3K36Me2, α-H3K36Me3, α-H4K16Ac, and α -H3K9Ac antibodies from whole cell extracts and quantified by ImageJ software from National Institutes of Health. α -H3 and α -H4 are used as loading controls for respective modifications. At least three separate experiments were done. Error bars show standard deviation. I, ZMYND8 silencing was done in 2 days of ATRA- or DMSO- treated SH-SY5Y cells. Similar experiments were performed with non-targeting siRNA, as negative control. Total mRNA level was analyzed by quantitative PCR, and GAPDH was used for normalization. Reference level was considered as 1. J, ZMYND8 knockdown in SH-SY5Y cells was scored by Western blotting after ATRA treatment for 2 days, with α-ZMYND8 antibody. GAPDH was used for normalization. Blots were quantified using ImageJ software from National Institutes of Health. K, alterations in the expression of neuronal markers (TUJ1, TAU, DRD2, NAV1.2, and SNAP25), glial markers (GFAP and VIM), and pluripotency marker REST were measured after ZMYND8 siRNA (or a non-targeting siRNA as negative control) transfection during 2 days of ATRA or DMSO treatment in SH-SY5Y cells. Total mRNA level was scored by quantitative PCR normalizing to GAPDH. Relative mRNA level was plotted as ATRA-treated differentiated cells over DMSO-treated undifferentiated cells. Reference level considered as 1. At least three separate experiments were done. Error bars show standard deviation.





FIGURE 6. **ZMYND8 interacts with RNA polymerase II phospho-Ser5 in a DNA-dependent manner.** *A*, ZMYND8 was co-immunoprecipitated from SH-SY5Y cells and immunoblotted with α -RNA polymerase II non-CTD (epitope at N terminus), α -RNA polymerase II phospho-Ser-5, and α -RNA polymerase II phospho-Ser-2 antibodies. IgG serves as negative control. *B–D*, similarly, RNA polymerase II non-CTD (*B*), RNA pol II phospho-Ser-5 (*C*), and RNA pol II phospho-Ser-2 (*D*) was co-immunoprecipitated from SH-SY5Y cells and immunoblotted with α -ZMYND8 antibody. *E*, co-IP of RNA pol II phospho-Ser-5 from 4 days ATRA- or DMSO-treated SH-SY5Y cells followed by immunoblotting with α -ZMYND8 antibody. IgG serves as negative control. *F*, RNA pol II phospho-Ser-5 was co-immunoprecipitated from SH-SY5Y cells after DNase I treatment of Iysates and immunoblotted with α -ZMYND8 antibody. IgG serves as negative control. *G*, ChIP assays were performed after ZMYND8 siRNA or a non-targeting siRNA transfection during 2 days of ATRA or DMSO treatment in SH-SY5Y cells with α -RNA pol II phospho-Ser-5 with IgG and represented as ATRA-treated differentiated cells over DMSO-treated undifferentiated cells.

and down-regulated (*HIPK3, BARD1,* and *ZNF687*) genes showed differential expression upon *ZMYND8* silencing (Fig. 7*B*). Previous studies have shown that silencing *CHD4* (an important chromatin remodeling subunit of NuRD) can alter global gene expression in HeLa cells (40). To understand the NuRD-associated functions of ZMYND8, we analyzed the differentially expressed gene sets upon silencing *ZMYND8* with that of *CHD4* (40). On careful examination, we found that only 40 up- and 71 down-regulated genes were commonly regulated by these factors (Fig. 7*C*). A detailed comparison of the clusters (Fig. 7*D*) and overlapping Venn diagram (Fig. 7*E*) of up/downregulated genes upon *ZMYND8* or *CHD4* silencing has been performed. Biological Analysis Network for the common gene regulatory pathways is represented in Fig. 7*F*. These results clearly indicate that ZMYND8 has a significant CHD4-independent role on a global platform.

ZMYND8 Is a Key Regulator of a Subset of ATRA-inducible Genes—While analyzing the microarray results upon silencing ZMYND8, we found that a number of genes, which were regulated by ZMYND8, also harbored the RARE motif and hence



FIGURE 7. **Regulation of global gene expression by ZMYND8 in a NuRD-independent mode.** *A*, clustering and heat maps of expression values for differentially expressed genes. Down-regulated genes are marked in *green*, and up-regulated genes are marked in *red*. From *left* to *right*, first three samples are control siRNA-treated and latter three samples are ZMYND8 siRNA-treated HeLa cells. *B*, validation of microarray analysis. *Bars* show candidate up-regulated and down-regulated genes after knocking down *ZMYND8* in HeLa cells. *185 rRNA* was used for normalization. Reference level was considered as 1. At least three individual experiments were performed. *Error bars* show standard deviation. *C*, Venn diagram showing the overlap between up- and down-regulated genes in *ZMYND8* or *CHD4* knocked down HeLa cells. *D*, clustering and heat maps of up- and down-regulated genes in *ZMYND8* knocked down and *CHD4* knocked down HeLa cells. *E*, overlapping Venn diagram for common differentials between *ZMYND8* and *CHD4*. The *pink circle* represents up-regulated genes in siCHD4, and the *green circle* is for down-regulated genes in siCHD4; the *yellow circle* is for up-regulated genes in siZMYND8. As they have common differential genes, so the overlapping areas are in different colors. *F*, networks for *ZMYND8* knocked down and *CHD4* knocked down HeLa cells based on the common biology. The genes whose regulation are opposite in the two networks are bordered in *black*. The genes are colored according to their fold change and sized based on their *p* value which is <0.05. *Green* and *red ellipses* denote down-regulation and up-regulation, respectively, and the processes are denoted by a *blue rectangle*.

can be considered as ATRA-responsive. A detailed list of differentially expressed genes as a sequel to ATRA treatment has been previously reported in HeLa cells (41). Upon *ZMYND8* silencing, we found an overlap of at least 90 up- and 83 downregulated candidates that are ATRA-inducible (Fig. 8*A*). Detailed cluster analyses of the up/down-regulated genes, which are simultaneously ATRA-responsive, have been represented in Fig. 8*B*. We further validated candidate up- and down-regulated genes upon silencing *ZMYND8*, which also harbors RARE motifs by qRT-PCR (Fig. 8*C*). Biological network for differentially expressed genes upon silencing of *ZMYND8* as well as harboring the RARE motif are represented in Fig. 8*D*. These results clearly indicate that ZMYND8 is indeed a regulator of a fraction of ATRA-inducible genes in a global context.

Discussion

Multifunctional transcription factors harbor conserved chromatin-binding modules and show differential affinity for

chromatin (42, 43). Essentially, these transcription factors are histone-interacting proteins (14), like ZMYND8, which has a distinct preference for modified histone H3 and H4 (Fig. 3B). Furthermore, ZMYND8 shows a preference for canonical histone H3.1, unlike ZMYND11 (Fig. 3A, panel I). A sequence alignment between these two proteins shows that certain key residues, including Asn-263 and Arg-265 (marked in *blue*), which were involved in mediating H3.3 binding through the H-bonding interaction in ZMYND11, is replaced by Cys-263 and Lys-265 in ZMYND8 (Fig. 3A, panel II). This possibly makes a difference in its choice for canonical histone H3.1 over its variant H3.3. However, among the five amino acids that are different between H3.1 and H3.3, Ala-31 of canonical H3.1 is substituted by Ser-31 in variant H3.3 and is probably an important determining factor for the preference of ZMYND8 (Fig. 3A, panel III).

The transcription factors with conserved chromatin-binding modules preferentially bind to modified histones (14). For





FIGURE 8. **ZMYND8 modulates RARE-harboring genes.** *A*, Venn diagram showing the overlap between up- and down-regulated genes in *ZMYND8* knocked down and total RARE-harboring genes in HeLa cells. *B*, clustering and heat maps of up- and down-regulated genes in *ZMYND8* knocked down and total RARE-harboring genes in HeLa cells. *C*, validation of microarray analysis. *Bars* show candidate RARE-harboring, up- and down-regulated genes after knocking down *ZMYND8* in HeLa cells. *185 rRNA* was used for normalization. Reference level was considered as 1. At least three separate experiments were done. *Error bars* show standard deviation. *D*, gene regulatory network for differentially expressed genes in *ZMYND8* knocked down and total RARE-harboring genes in *ectangles*, and miRNAs are *triangular* in shape. The genes whose regulation are opposite in the two networks are bordered in *black. Green* denotes down-regulation, and *red* denotes up-regulation. The color shade of nodes differs due to their fold change. The size of the nodes is as per their *p* value which is <0.05.

example, the CREB-binding protein bromodomain binds to H3K36Ac/H3K56Ac/H4K20Ac (44, 45) in a monovalent manner, and bromodomain PHD finger transcription factor/PHD finger binds to H4K16Ac/H3K4Me3 (15) in a multi-valent fashion. In our study, ZMYND8 preferentially binds to H3.1K36Me2/Me3 (Fig. 2, *C, panel I,* and *F, panel I*) and H4K16Ac (Fig. 2, *D*, *panel I*, and *F*, *panel II*). Although isolated bromodomain of ZMYND8 could bind to H4K16Ac (Fig. 2*D*, *panel II*), PWWP domain could interact with H3.1K36Me2/Me3 only when it was integrated along with bromodomain and PHD finger (Fig. 2*C*, *panels I–III*). For stabilization of conformation of the aromatic pocket in PWWP domain, the presence

of other supporting domains, i.e. bromodomain and PHD finger, is essential. This comprehensive reader function can also be seen in case of ZMYND11 (14). To understand the binding preference of ZMYND8 for H4K16Ac in comparison with ZMYND11, we performed sequence alignment between the two proteins (Fig. 2G) and subsequently molecular modeling studies (Fig. 2, H–J). Several bromodomain proteins harbor YN residues in their active site (46). We found that ZMYND8 has Tyr-Y227 and Asn-228 amino acids in its bromodomain, which are absent in ZMYND11. The site-directed mutagenesis approach confirmed the Y227A/N228A mutant has reduced H4K16Ac binding ability (Fig. 2K). To find out the preference for modified histone recognition by ZMYND8 in cells, we performed the co-IP experiment that supported the better interaction between ZMYND8 and H3K36Me2 as compared with H3K36Me3 (Fig. 3B), in conformity with in vitro fluorescence titration assays (Fig. 2F). In parallel, the co-IP assay also confirmed the interaction of ZMYND8 with H4K16Ac ex vivo (Fig. 3B).

H3K36 methylation by Set2 recruits the Rpd3S histone deacetylase complex, which deacetylates the neighboring nucleosomes preventing cryptic transcription initiation within the gene body (47). Because ZMYND8 binds to H3K36Me2, it might have additional roles in modulating nucleosomal integrity over the coding regions preventing cryptic transcription initiation. Remarkably, the human orthologue of Drosophila melanogaster MOF (males-absent-on-the-first, a key member of the MYST family (hMOF)-mediated acetylation of H4K16) causes a recruitment of BRD4 and pTEFB to chromatin leading to a release of RNA polymerase II pausing (48, 49). In this context ZMYND8 through its chromatin reader ability might be instrumental in recruiting these factors onto chromatin thereby promoting processive transcription. The di- and trimethylated H3K36 at the gene body shows a distinct distribution pattern, where H3K36Me2 is adjacent to promoters and H3K36Me3 accumulates at the 3' end of the gene (47, 50). Although H3K36Me2 leads to elevated H4K16Ac, H3K36Me3 compensates it (50). The preferential interaction of ZMYND8 to H3K36Me2/H4K16Ac indicates its ability to modulate higher order chromatin structure and hence transcription. This could be possible through its ability to act as a chromatin reader, which further helps in recruiting a chromatin remodeling machinery complex steering transcription activation. Interestingly, as ZMYND8-enriched genes (RRAS2, TGFA, MET, HOXA9, TP53, and WNT1) (Fig. 3, E and F, panel II) are intricately involved in pathways regulating cell proliferation, differentiation, and development (51-56), our results indicate a possible involvement of ZMYND8 in these processes. We elucidated that a higher occupancy of ZMYND8 to these developmentally regulated genes is due to its chromatin reader function, as there is also a significant enrichment of H3K36Me2/ H4K16Ac marks in these genes (Fig. 3, C and D, panel I). Furthermore, we observed an increased recruitment of ZMYND8 at the gene body of ATRA-inducible genes (TUJ1, TAU, DRD2, NAV1.2 and SNAP25) through its modified histone-binding ability (Fig. 5, E-G). However, we also observed robust enrichment of ZMYND8 at the promoter harboring the RARE sequence of these RA-responsive genes (Fig. 5D) and

speculated its association with the core transcription machinery.

As RNA polymerase II transcribes a gene, there is a distinct alteration in its C-terminal domain phosphorylation status (57), which is instrumental in a dynamic association of factors that interact with the enzyme. We observed a strong interaction of ZMYND8 with RNA pol II S5P in a DNA-mediated manner (Fig. 6, *A*, *C*, and *F*). This interaction could be steered by some other factor(s) that promotes transcription initiation and brings ZMYND8 and RNA pol II complex to the promoter site. ZMYND8 might also be assisting in the recruitment of the RNA pol II complex through its selective binding to the H3K36Me2enriched region of the genome located at the promoter proximal site. ZMYND11, however, modulates the activity of RNA pol II S2P at the 3' end of the gene through its H3.3K36Me3 recognizing ability (14). Interestingly, the association of ZMYND8 with RNA pol II S5P is retained in absence of ATRA (Fig. 6*E*), further confirming that a stoichiometric complex formation between the two requires a DNA template. Indeed, we observed that the interaction is significantly reduced in the presence of DNase I (Fig. 6F). Furthermore, in the absence of ZMYND8, there was a significant reduction in RNA pol II S5P occupancy even upon ATRA induction, indicating that ZMYND8 is an indispensable component of initiating RNA pol II machinery (Fig. 6*G*).

Finally, we wanted to understand the role of ZMYND8, an integral component of transcription machinery, in regulating global gene expression. Previous studies have reported that ZMYND8 is a functional component of the transcription repression complex NuRD (58, 59) and targets it to the DNA damage response site (23). CHD3/4 is responsible for the ATPdependent chromatin remodeling function of NuRD (35, 60). In this study, we tried to understand the CHD4-independent function of ZMYND8 in perspective of gene expression. Microarray analysis clearly indicated that ZMYND8 regulates a large class of genes that are unique from those regulated by CHD4 (Fig. 7). Interestingly, subsets of genes that are differentially expressed upon silencing of ZMYND8 also harbor the RARE motif and hence are ATRA-responsive (Fig. 8). ZMYND8 itself harbors the RARE sequence and is regulated by RA (Fig. 5, B and C). Because ZMYND8 has a preference for canonical histone H3.1 over variant H3.3, we also analyzed whether the gene targets of ZMYND8 have a depleted occupancy of H3.3. However, a significant number of ZMYND8 target genes is found to harbor H3.3 (data not shown). It would be interesting to understand the mechanism of transcription regulation by ZMYND8 in H3.1 versus H3.3-enriched genes.

In summary, we found that ZMYND8, a transcription regulator, is a putative chromatin reader. Through its specific motifs as well as amino acid residues, it exerts its chromatin-binding ability. Furthermore, it shows its preferential interaction with canonical histone H3.1K36Me2 and H4K16Ac. Interestingly, *ZMYND8* is itself an RA-inducible gene, and through its modified histone-binding ability it regulates the expression of other ATRA-responsive genes. Furthermore, we show that ZMYND8 is indeed associated with transcription initiation-competent RNA pol II S5P in a DNA template-dependent manner. Although it is a transcription factor, the mechanism underlying



the gene expression regulation by ZMYND8 has remained elusive. Hence, this study is an attempt to decipher the so far uncharacterized ability of ZMYND8 to modulate gene expression. Further study may uncover its possible role in lineage commitment during development.

Author Contributions—C. D. and S. R. conceived the study and designed the experiments. S. A., S. S., M. B., I. S., S. S., and D. K. S. performed the experiments and analyzed the data. C. D., S. R., M. B., S. A., and S. S. wrote the paper. All authors discussed the paper and commented on the manuscript.

Acknowledgments—We thank Prof. Hideaki Tagami for FLAG-H3.1/ H3.3 plasmids. We thank Prof. Jessica K. Tyler for critical comments on the manuscript and Prof. Tapas K. Kundu and Prof. Dipak Dasgupta for helpful discussions. We thank Payal Chakraborty and Madavan Vasudevan from Bionivid Technology Pvt. Ltd. for their assistance with microarray experiments and data analysis. We also thank Rajarshi Chakrabarti for assistance with OLYMPUS FLUOVIEW FV1000 confocal imaging.

References

- Zhang, Y., LeRoy, G., Seelig, H. P., Lane, W. S., and Reinberg, D. (1998) The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. *Cell* 95, 279–289
- Tong, J. K., Hassig, C. A., Schnitzler, G. R., Kingston, R. E., and Schreiber, S. L. (1998) Chromatin deacetylation by an ATP-dependent nucleosome remodeling complex. *Nature* 395, 917–921
- Yun, M., Wu, J., Workman, J. L., and Li, B. (2011) Readers of histone modifications. *Cell Res.* 21, 564–578
- Musselman, C. A., Lalonde, M. E., Côté, J., and Kutateladze, T. G. (2012) Perceiving the epigenetic landscape through histone readers. *Nat. Struct. Mol. Biol.* **19**, 1218–1227
- Malovannaya, A., Lanz, R. B., Jung, S. Y., Bulynko, Y., Le, N. T., Chan, D. W., Ding, C., Shi, Y., Yucer, N., Krenciute, G., Kim, B. J., Li, C., Chen, R., Li, W., Wang, Y., O'Malley, B. W., and Qin, J. (2011) Analysis of the human endogenous coregulator complexome. *Cell* 145, 787–799
- Eberl, H. C., Spruijt, C. G., Kelstrup, C. D., Vermeulen, M., and Mann, M. (2013) A map of general and specialized chromatin readers in mouse tissues generated by label-free interaction proteomics. *Mol. Cell* 49, 368–378
- Zeng, W., Kong, Q., Li, C., and Mao, B. (2010) *Xenopus* RCOR2 (REST corepressor 2) interacts with ZMYND8, which is involved in neural differentiation. *Biochem. Biophys. Res. Commun.* 394, 1024–1029
- Bierkens, M., Krijgsman, O., Wilting, S. M., Bosch, L., Jaspers, A., Meijer, G. A., Meijer, C. J., Snijders, P. J., Ylstra, B., and Steenbergen, R. D. (2013) Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. *Genes Chromosomes Cancer* 52, 56–68
- Edgren, H., Murumagi, A., Kangaspeska, S., Nicorici, D., Hongisto, V., Kleivi, K., Rye, I. H., Nyberg, S., Wolf, M., Borresen-Dale, A. L., and Kallioniemi, O. (2011) Identification of fusion genes in breast cancer by paired-end RNA-sequencing. *Genome Biol.* 12, R6
- Eichmuller, S., Usener, D., Dummer, R., Stein, A., Thiel, D., and Schadendorf, D. (2001) Serological detection of cutaneous T-cell lymphoma-associated antigens. *Proc. Natl. Acad. Sci. U.S.A.* 98, 629 – 634
- Balmer, J. E., and Blomhoff, R. (2002) Gene expression regulation by retinoic acid. J. Lipid Res. 43, 1773–1808
- Liu, H., and Naismith, J. H. (2008) An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. *BMC Biotechnol.* 8, 91
- 13. Das, C., Hizume, K., Batta, K., Kumar, B. R., Gadad, S. S., Ganguly, S., Lorain, S., Verreault, A., Sadhale, P. P., Takeyasu, K., and Kundu, T. K.

(2006) Transcriptional coactivator PC4, a chromatin-associated protein, induces chromatin condensation. *Mol. Cell. Biol.* **26**, 8303–8315

- Wen, H., Li, Y., Xi, Y., Jiang, S., Stratton, S., Peng, D., Tanaka, K., Ren, Y., Xia, Z., Wu, J., Li, B., Barton, M. C., Li, W., Li, H., and Shi, X. (2014) ZMYND11 links histone H3.3K36me3 to transcription elongation and tumour suppression. *Nature* 508, 263–268
- Ruthenburg, A. J., Li, H., Milne, T. A., Dewell, S., McGinty, R. K., Yuen, M., Ueberheide, B., Dou, Y., Muir, T. W., Patel, D. J., and Allis, C. D. (2011) Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions. *Cell* 145, 692–706
- Wysocka, J. (2006) Identifying novel proteins recognizing histone modifications using peptide pull-down assay. *Methods* 40, 339–343
- 17. Chakrabarti, S., Bhattacharyya, D., and Dasgupta, D. (2000) Structural basis of DNA recognition by anticancer antibiotics, chromomycin A(3), and mithramycin: roles of minor groove width and ligand flexibility. *Biopolymers* **56**, 85–95
- Eswar, N., Eramian, D., Webb, B., Shen, M. Y., and Sali, A. (2008) Protein structure modeling with MODELLER. *Methods Mol. Biol.* 426, 145–159
- Das, C., Gadad, S. S., and Kundu, T. K. (2010) Human positive coactivator 4 controls heterochromatinization and silencing of neural gene expression by interacting with REST/NRSF and CoREST. J. Mol. Biol. 397, 1–12
- Zhan, X., Shi, X., Zhang, Z., Chen, Y., and Wu, J. I. (2011) Dual role of Brg chromatin remodeling factor in Sonic hedgehog signaling during neural development. *Proc. Natl. Acad. Sci. U.S.A.* 108, 12758–12763
- Li, J., and Stern, D. F. (2005) DNA damage regulates Chk2 association with chromatin. J. Biol. Chem. 280, 37948 –37956
- Tsai, W. W., Wang, Z., Yiu, T. T., Akdemir, K. C., Xia, W., Winter, S., Tsai, C. Y., Shi, X., Schwarzer, D., Plunkett, W., Aronow, B., Gozani, O., Fischle, W., Hung, M. C., Patel, D. J., and Barton, M. C. (2010) TRIM24 links a non-canonical histone signature to breast cancer. *Nature* 468, 927–932
- 23. Gong, F., Chiu, L. Y., Cox, B., Aymard, F., Clouaire, T., Leung, J. W., Cammarata, M., Perez, M., Agarwal, P., Brodbelt, J. S., Legube, G., and Miller, K. M. (2015) Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination. *Genes Dev.* 29, 197–211
- Dhayalan, A., Rajavelu, A., Rathert, P., Tamas, R., Jurkowska, R. Z., Ragozin, S., and Jeltsch, A. (2010) The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and guides DNA methylation. *J. Biol. Chem.* 285, 26114–26120
- Mansfield, R. E., Musselman, C. A., Kwan, A. H., Oliver, S. S., Garske, A. L., Davrazou, F., Denu, J. M., Kutateladze, T. G., and Mackay, J. P. (2011) Plant homeodomain (PHD) fingers of CHD4 are histone H3-binding modules with preference for unmodified H3K4 and methylated H3K9. *J. Biol. Chem.* 286, 11779–11791
- Wu, H., Zeng, H., Lam, R., Tempel, W., Amaya, M. F., Xu, C., Dombrovski, L., Qiu, W., Wang, Y., and Min, J. (2011) Structural and histone-binding ability characterizations of human PWWP domains. *PLoS ONE* 6, e18919
- Taylor, G. C., Eskeland, R., Hekimoglu-Balkan, B., Pradeepa, M. M., and Bickmore, W. A. (2013) H4K16 acetylation marks active genes and enhancers of embryonic stem cells, but does not alter chromatin compaction. *Genome Res.* 23, 2053–2065
- Kuo, A. J., Cheung, P., Chen, K., Zee, B. M., Kioi, M., Lauring, J., Xi, Y., Park, B. H., Shi, X., Garcia, B. A., Li, W., and Gozani, O. (2011) NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. *Mol. Cell* 44, 609–620
- Horikoshi, N., Kumar, P., Sharma, G. G., Chen, M., Hunt, C. R., Westover, K., Chowdhury, S., and Pandita, T. K. (2013) Genome-wide distribution of histone H4 lysine 16 acetylation sites and their relationship to gene expression. *Genome Integr.* 4, 3
- Fang, H. B., Mi, Y., Zhang, Y., Wu, N. H., and Shen, Y. F. (2010) HDAC3 augments the autoregulation of neuroD gene in P19 cells. *Neuroreport* 21, 19–23
- Musch, T., Oz, Y., Lyko, F., and Breiling, A. (2010) Nucleoside drugs induce cellular differentiation by caspase-dependent degradation of stem cell factors. *PLoS ONE* 5, e10726
- 32. Chen, Q., Zhou, Z., Zhang, L., Xu, S., Chen, C., and Yu, Z. (2014) The cellular distribution and Ser262 phosphorylation of tau protein are regulated by BDNF *in vitro*. *PLoS ONE* **9**, e91793

SASBMB

- 33. Singh, A., Rokes, C., Gireud, M., Fletcher, S., Baumgartner, J., Fuller, G., Stewart, J., Zage, P., and Gopalakrishnan, V. (2011) Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCF(β-TRCP) in neuroblastoma cells. *Cancer* **117**, 5189–5202
- Wernicke, C., Hellmann, J., Finckh, U., and Rommelspacher, H. (2010) Chronic ethanol exposure changes dopamine D2 receptor splicing during retinoic acid-induced differentiation of human SH-SY5Y cells. *Pharma*col. Rep. 62, 649–663
- 35. Ahringer, J. (2000) NuRD and SIN3 histone deacetylase complexes in development. *Trends Genet.* **16**, 351–356
- Widestrand, A., Faijerson, J., Wilhelmsson, U., Smith, P. L., Li, L., Sihlbom, C., Eriksson, P. S., and Pekny, M. (2007) Increased neurogenesis and astrogenesis from neural progenitor cells grafted in the hippocampus of GFAP-/- Vim-/- mice. *Stem Cells* 25, 2619–2627
- Poloni, A., Maurizi, G., Foia, F., Mondini, E., Mattiucci, D., Ambrogini, P., Lattanzi, D., Mancini, S., Falconi, M., Cinti, S., Olivieri, A., and Leoni, P. (2015) Glial-like differentiation potential of human mature adipocytes. *J. Mol. Neurosci.* 55, 91–98
- Poleshko, A., Einarson, M. B., Shalginskikh, N., Zhang, R., Adams, P. D., Skalka, A. M., and Katz, R. A. (2010) Identification of a functional network of human epigenetic silencing factors. *J. Biol. Chem.* 285, 422–433
- 39. Kloet, S. L., Baymaz, H. I., Makowski, M., Groenewold, V., Jansen, P. W., Berendsen, M., Niazi, H., Kops, G. J., and Vermeulen, M. (2015) Towards elucidating the stability, dynamics and architecture of the nucleosome remodeling and deacetylase complex by using quantitative interaction proteomics. *FEBS J.* **282**, 1774–1785
- Nishibuchi, G., Shibata, Y., Hayakawa, T., Hayakawa, N., Ohtani, Y., Sinmyozu, K., Tagami, H., and Nakayama, J. (2014) Physical and functional interactions between the histone H3K4 demethylase KDM5A and the nucleosome remodeling and deacetylase (NuRD) complex. *J. Biol. Chem.* 289, 28956–28970
- Lalevée, S., Anno, Y. N., Chatagnon, A., Samarut, E., Poch, O., Laudet, V., Benoit, G., Lecompte, O., and Rochette-Egly, C. (2011) Genome-wide *in silico* identification of new conserved and functional retinoic acid receptor response elements (direct repeats separated by 5 bp). *J. Biol. Chem.* 286, 33322–33334
- Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., and Patel, D. J. (2007) How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. *Nat. Struct. Mol. Biol.* 14, 1025–1040
- 43. Falciola, L., Spada, F., Calogero, S., Langst, G., Voit, R., Grummt, I., and Bianchi, M. E. (1997) High mobility group 1 protein is not stably associated with the chromosomes of somatic cells. *J. Cell Biol.* **137**, 19–26
- Das, C., Roy, S., Namjoshi, S., Malarkey, C. S., Jones, D. N., Kutateladze, T. G., Churchill, M. E., and Tyler, J. K. (2014) Binding of the histone chaperone ASF1 to the CBP bromodomain promotes histone acetylation. *Proc. Natl. Acad. Sci. U.S.A.* 111, E1072–E1081
- Zeng, L., Zhang, Q., Gerona-Navarro, G., Moshkina, N., and Zhou, M. M. (2008) Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300. *Structure* 16, 643–652

- Filippakopoulos, P., and Knapp, S. (2012) The bromodomain interaction module. *FEBS Lett.* 586, 2692–2704
- Youdell, M. L., Kizer, K. O., Kisseleva-Romanova, E., Fuchs, S. M., Duro, E., Strahl, B. D., and Mellor, J. (2008) Roles for Ctk1 and Spt6 in regulating the different methylation states of histone H3 lysine 36. *Mol. Cell Biol.* 28, 4915–4926
- Kapoor-Vazirani, P., Kagey, J. D., and Vertino, P. M. (2011) SUV420H2mediated H4K20 trimethylation enforces RNA polymerase II promoterproximal pausing by blocking hMOF-dependent H4K16 acetylation. *Mol. Cell. Biol.* 31, 1594–1609
- Zippo, A., Serafini, R., Rocchigiani, M., Pennacchini, S., Krepelova, A., and Oliviero, S. (2009) Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. *Cell* 138, 1122–1136
- Bell, O., Wirbelauer, C., Hild, M., Scharf, A. N., Schwaiger, M., MacAlpine, D. M., Zilbermann, F., van Leeuwen, F., Bell, S. P., Imhof, A., Garza, D., Peters, A. H., and Schübeler, D. (2007) Localized H3K36 methylation states define histone H4K16 acetylation during transcriptional elongation in *Drosophila. EMBO J.* 26, 4974–4984
- Larive, R. M., Abad, A., Cardaba, C. M., Hernández, T., Cañamero, M., de Álava, E., Santos, E., Alarcón, B., and Bustelo, X. R. (2012) The Ras-like protein R-Ras2/TC21 is important for proper mammary gland development. *Mol. Biol. Cell* 23, 2373–2387
- 52. Kawamura, K., Kawamura, N., Kumagai, J., Fukuda, J., and Tanaka, T. (2007) Tumor necrosis factor regulation of apoptosis in mouse preimplantation embryos and its antagonism by transforming growth factor α /phosphatidylinositol 3-kinase signaling system. *Biol. Reprod.* **76**, 611–618
- 53. Li, Y. Q., Ren, X. Y., He, Q. M., Xu, Y. F., Tang, X. R., Sun, Y., Zeng, M. S., Kang, T. B., Liu, N., and Ma, J. (2015) MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET. *Cell Death Dis.* 6, e1618
- Gersten, M., Zhou, D., Azad, P., Haddad, G. G., and Subramaniam, S. (2014) Wnt pathway activation increases hypoxia tolerance during development. *PLoS ONE* 9, e103292
- Gardiner, D. M., Blumberg, B., Komine, Y., and Bryant, S. V. (1995) Regulation of HoxA expression in developing and regenerating axolotl limbs. *Development* 121, 1731–1741
- 56. Sammons, M. A., Zhu, J., Drake, A. M., and Berger, S. L. (2015) TP53 engagement with the genome occurs in distinct local chromatin environments via pioneer factor activity. *Genome Res.* 25, 179–188
- 57. Phatnani, H. P., and Greenleaf, A. L. (2006) Phosphorylation and functions of the RNA polymerase II CTD. *Genes Dev.* **20**, 2922–2936
- Allen, H. F., Wade, P. A., and Kutateladze, T. G. (2013) The NuRD architecture. *Cell. Mol. Life Sci.* 70, 3513–3524
- Feng, Q., and Zhang, Y. (2003) The NuRD complex: linking histone modification to nucleosome remodeling. *Curr. Top. Microbiol. Immunol.* 274, 269–290
- O'Shaughnessy, A., and Hendrich, B. (2013) CHD4 in the DNA-damage response and cell cycle progression: not so NuRDy now. *Biochem. Soc. Trans.* 41, 777–782

